Key Takeaways PKX will launch a North American DLE project to test commercial-scale lithium extraction. PKX's DLE technology cuts water use, speeds production and reduces environmental impacts. PKX aims to operate a demo plant by 2027 and support commercial deployment by 2028. POSCO Holdings Inc. (PKX - Free Report) has taken a major step toward strengthening its lithium supply chain by becoming the first Korean company to pursue a commercial-scale demonstration of Direct Lithium Extraction (DLE) technology in the United States. The initiative marks a significant milestone in the company’s efforts to secure critical battery raw materials through next-generation extraction methods.
POSCO announced that it will launch a DLE demonstration project in North America to validate the economic feasibility and scalability of the technology. DLE technology extracts lithium directly from brine using specialized absorbents and separation processes. The method significantly reduces water usage, shortens production cycles and minimizes environmental impacts.
The project is part of POSCO’s broader strategy to establish a stable and diversified lithium supply network amid growing global demand for electric vehicle batteries and energy storage systems. By developing its own extraction capabilities, the company seeks to strengthen its competitiveness in the battery materials sector and reduce dependence on conventional lithium sources.
The demonstration facility will allow POSCO to test the commercial viability of its proprietary DLE technology under real-world operating conditions. POSCO plans to complete and begin operating the demonstration plant by 2027, to lay the groundwork for commercial deployment by 2028.
Per POSCO, the demonstration project represents a strategic investment designed to secure next-generation lithium extraction technology and strengthen the company’s position in the global lithium market. Leveraging its technological expertise and competitive advantages, POSCO aims to further enhance the competitiveness of its global lithium business and expand its presence in key markets, including North America.
Shares of PKX have gained 32.7% in the past year against the industry’s 3.6% decline.
Image Source: Zacks Investment Research
PKX Zacks Rank & Other Key PicksPKX currently carries a Zacks Rank #2 (Buy).
Other top-ranked stocks in the Conglomerates space include ITT Inc. (ITT - Free Report) , Marubeni Corporation (MARUY - Free Report) and Griffon Corporation (GFF - Free Report) . ITT, MARUY and GFF carry a Zacks Rank #2. You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.
The Zacks Consensus Estimate for ITT’s current-year earnings is pegged at $7.9 per share, indicating a 17.6% year-over-year increase. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with the average earnings surprise being 5.8%.
The Zacks Consensus Estimate for MARUY’s current-year earnings is pegged at $23.86 per share, indicating an 8.8% year-over-year decrease. Shares of MARUY have gained 50.8% over the past year.
The Zacks Consensus Estimate for GFF’s current fiscal-year earnings is pegged at $5.17 per share. Its earnings beat the Zacks Consensus Estimate in three of the trailing four quarters and missed once, with the average earnings surprise being 3.3%.
SummaryRealty Income is rated Strong Buy, offering a 5.2% yield, consistent dividend growth, and trades at a significant discount to fair value.O’s diversified, high-occupancy portfolio and disciplined property selection underpin its stability and outperformance during periods of market stress.Forward total return estimates range from 11.1% to 14.5% annually, driven by dividend yield, valuation re-rating, and 4% expected FFO/dividend growth.O’s triple-net lease model, investment-grade balance sheet, and global expansion support long-term income growth and risk mitigation.Looking for a helping hand in the market? Members of Friedrich Global Research get exclusive ideas and guidance to navigate any climate. Learn More »Sitewide Sale 2026: Get 20% Off fatido/iStock via Getty Images
Introduction
I consider Realty Income (O) to be more like a bond (but better): safe, with steady monthly income over time but with the benefit of a rising yield and some potential appreciation. Its price maintains an inverse
15.76K Followers
Analyst’s Disclosure: I/we have a beneficial long position in the shares of O either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
DISCLAIMER: This analysis is not advice to buy or sell this or any stock; it is just pointing out an objective observation of unique patterns that developed from our research. Factual material is obtained from sources believed to be reliable, but the poster is not responsible for any errors or omissions, or for the results of actions taken based on information contained herein. Nothing herein should be construed as an offer to buy or sell securities or to give individual investment advice.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
Duke Energy (NYSE:DUK | DUK Price Prediction) is a stock built for decades of ownership because its regulated monopoly model converts essential grid infrastructure into contractually structured cash flow, and that cash flow has now funded 100 consecutive years of quarterly dividends.
Pillar 1: A Durable Regulated Moat Duke is a vertically integrated, rate-regulated electric and gas utility serving roughly 10 million customers across the Carolinas, Florida, Indiana, Ohio, Kentucky, and Tennessee. State commissions, not competitors, set its allowed returns, and that framework virtually guarantees recovery on capital deployed to maintain the grid. The company is running the industry’s largest regulated capital plan at $103 billion over five years, targeting 9.6% earnings base growth through 2030. Customer counts grew 1.4% year over year in the most recent quarter, and rates remain below the national average with increases running below inflation.
Pillar 2: A Century of Dividends, Still Growing The income case is the heart of the forever thesis. Duke just paid its $1.065 quarterly dividend in May, with a yield of 3.41% on a $4.24 annualized payout. CFO Brian Savoy framed the milestone bluntly on the Q1 call: “This milestone marks a long-dated commitment to the dividend that’s directly tied to the company’s financial strength, regulatory execution and disciplined long-term investments.” The quarterly payout has stepped up steadily, from $0.945 in 2019 to $1.065 in 2026, and full-year operating cash flow reached $12.33 billion in 2025.
Pillar 3: A Business Built to Outlast Cycles Electricity is the last bill a household stops paying, and Duke’s regulated returns are insulated from the market mood. FY 2025 adjusted EPS landed at $6.31 on revenue of $32.24 billion, up 6.19%, and Q1 2026 delivered $1.93 in adjusted EPS, a 7.51% beat. Management reaffirmed $6.55 to $6.80 EPS guidance for 2026 and 5% to 7% annual growth through 2030, with 7.6 gigawatts of AI and advanced manufacturing demand already locked in under Electric Service Agreements. A low beta of 0.379 reflects what that contractual structure produces: a stock that stays steady through market headlines.
The Scenario Where It Lags Duke will underperform in a risk-on bull market. When high-beta technology names run, a utility trading at 19 times earnings will look slow. Higher interest expense and coal ash remediation costs are real headwinds, and industrial sales slipped 2.1% year over year in Q1. None of that changes the forever thesis. Rate base growth is contractually structured, not market-dependent, and the 4.45% 10-year Treasury yield is already priced into a stock that has still returned 128.29% over the past decade while paying dividends every quarter.
The thesis here is structural durability, not short-term trading appeal.
Final $830,000 round completes the Foundation's more than $1 million America250 investment across the six states Duke Energy serves , /PRNewswire/ -- From new heritage trails and museum exhibits to preservation projects and public art, communities across Duke Energy's six-state service area will have new ways to explore the local stories behind America's 250th anniversary.
The Duke Energy Foundation is awarding nearly $830,000 in 54 grants to nonprofit organizations, cultural institutions and community partners in North Carolina, South Carolina, Florida, Indiana, Ohio and Kentucky.
The grants mark the final round of the Foundation's America250 initiative, completing a more than $1 million investment tied to the nation's anniversary and helping communities bring local history to life in new, more accessible ways.
Why This Matters
The latest round supports projects that preserve local heritage and expand civic learning across the communities they serve.
"America's 250th anniversary is an opportunity to recognize that history is not only national – it is local, personal and still shaping the places we call home," said Loree Elswick, president of the Duke Energy Foundation. "Through these grants, we're helping communities bring those stories forward in ways that invite people to learn, reflect and connect."
What This Enables
Across Duke Energy's service territories, these grants will support efforts such as:
Hosting the Smithsonian's traveling "Americans" exhibition as part of a six-week community initiative exploring American identity in Darlington County, South Carolina. Restoring a 1947 railroad locomotive tied to historic power plants, preserving a piece of local industrial history in Vigo County, Indiana. Bringing local history programming to rural communities through statewide "Homegrown History" community events led by the North Carolina Public Television Foundation. Creating a recurring constitutional exhibit with interactive displays and school-ready "history trunk" materials at the Dunedin History Museum in Florida. Supporting Cincinnati's BLINK public art exhibition, with installations that highlight regional identity and shared history across Ohio and Kentucky. The Bigger Picture
Earlier this spring, the Foundation awarded 32 grants to revitalize parks, green spaces and shared community places, and in May it supported veterans' career pathways with more than $250,000 invested in workforce development programs to help veterans gain job-ready skills and build pathways to in-demand civilian careers.
The Foundation also awarded $250,000 to the Trust for the National Mall to support the expansion of a free digital platform that enables communities nationwide to experience the National Mall's monuments and history.
"Growing up, I was one of those kids who did not have the funding to visit," said Jeremy Goldstein, vice president of programs at the Trust for the National Mall. "The Duke Energy Foundation is helping ensure that the platform is accessible to every student in America, and this is only the beginning."
Duke Energy Foundation
The Duke Energy Foundation provides nearly $30 million annually in philanthropic support to meet the needs of communities where Duke Energy customers live and work. The Foundation is funded by Duke Energy shareholders.
Duke Energy
Duke Energy (NYSE: DUK), a Fortune 150 company headquartered in Charlotte, N.C., is one of America's largest energy holding companies. The company's electric utilities serve 8.7 million customers in North Carolina, South Carolina, Florida, Indiana, Ohio and Kentucky, and collectively own 55,700 megawatts of energy capacity. Its natural gas utilities serve 1.6 million customers in North Carolina, South Carolina, Ohio and Kentucky.
Duke Energy is executing an energy modernization strategy, keeping customer value at the forefront as it invests in electric grid upgrades and efficient generation resources to strengthen the system and serve growing energy needs.
More information is available at duke-energy.com. Follow Duke Energy on X, LinkedIn, Instagram, TikTok and Facebook for stories about the people and innovations powering its communities.
New solution analyzes TV creative using performance signals, helping advertisers drive consumer engagement, including an average 13% campaign performance improvement1
SAN FRANCISCO--(BUSINESS WIRE)--tvScientific by Pinterest, the performance TV advertising platform, today announced Creative Advisor, the industry's new AI-powered creative optimization tool designed to help advertisers adjust their CTV creative for improved business outcomes and maximize the effectiveness of their media investment.
Creative Advisor analyzes millions of creative elements using proprietary AI models trained on years of real-world CTV performance data and outcome data2. The technology evaluates video ad elements, including messaging, audio, logo visibility, brand presence, and calls to action, then surfaces predictive recommendations designed to improve campaign performance and maximize the impact of every media dollar.
As Performance TV becomes an increasingly important channel for modern marketers3, creative remains one of the biggest drivers of campaign outcomes, yet one of the hardest to quantify before launch. Creative Advisor brings predictive intelligence to the creative process, helping advertisers evaluate and optimize new TV creative before media spend begins. Its recommendations can also be used to continuously refine and optimize existing ad creative, allowing advertisers to understand which creative decisions drive engagement, conversion, and business results.
“We’re excited to bring AI-powered optimization to TV ad creative,” said Jason Fairchild, CEO of tvScientific by Pinterest. “What makes Creative Advisor different is the data foundation behind it. The platform is powered by our proprietary creative intelligence dataset, built from tens of thousands of CTV creatives, millions of creative elements, and years of real-world performance signals. That allows us to identify which creative attributes are most likely to drive results and give advertisers actionable guidance rooted in proven outcomes, not assumptions. I predict this degree of element-level optimization, combined with advances in ML-based CTV optimization technologies, will more than double performance for TV advertisers in the foreseeable future.”
Creative Advisor assigns each video ad a predictive Creative Strength score and provides advertisers with a detailed assessment of creative effectiveness across key performance-driving signals. The platform is supported by a dedicated creative services team whose expert guidance helps advertisers translate creative insights into stronger-performing TV creative.
“Creative Advisor analyzed our existing creative and provided recommendations we could implement quickly. By making small changes to the visibility of our branding throughout the ad, we drove more site visits without rebuilding the entire spot,” said Anastasia Jenkin, Head of Affiliate and Creator Partnerships at HigherDOSE.
Early testing across multiple advertisers has demonstrated the predictive power of Creative Advisor, with brands seeing an average 13% improvement in campaign performance4 after optimizing creative based on the platform's recommendations.
Creative Advisor is currently available by request through tvScientific, including hands-on implementation of creative optimization guidance from creative and performance teams.
The launch underscores tvScientific by Pinterest’s broader vision for Performance TV, combining advanced AI, real-world outcome measurement, and consumer engagement insights to help advertisers drive stronger business results across streaming environments.
For more information, visit tvScientific’s Creative Advisor.
About tvScientific by Pinterest
tvScientific by Pinterest is an advertising platform built for Performance TV, helping brands and apps reach future customers earlier, optimize toward real business outcomes, and prove TV’s impact across the funnel. By combining Pinterest’s predictive intent signal with tvScientific’s AI-powered optimization and deterministic measurement, the platform helps advertisers turn earlier intent into measurable action across traffic, sales, installs, and more. With flexible outcome-based buying, tvScientific by Pinterest makes TV advertising more accessible, accountable, and measurable for businesses of all sizes.
1 tvScientific by Pinterest Internal Data, US, 4/2026-5/2026. N = 5, KPI = Website traffic.
2 tvScientific by Pinterest Internal Data, US, 2024-2026
3 tvScientific by Pinterest State of Performance TV Report, 2026
4 tvScientific by Pinterest Internal Data, US, 4/2026-5/2026. N = Website traffic.
HomeIndustriesMediaDeal values Roku at an 11% premium — and comes after the stock had already soared 20% on a report that a sale might be in the worksPublished: June 15, 2026 at 8:18 a.m. ET
Roku's stock rallies to a four-year high after agreeing to be bought by Fox in a deal valued at $22 billion. Photo: Getty ImagesShares of Roku rose in early Monday trading after the streaming platform agreed to be bought by Fox Corp. in a cash-and-stock deal valued at $22 billion.
The announcement comes after Roku’s stock ROKU soared 20.1% on Friday, when Bloomberg reported that Roku had held talks with a media company about a potential sale.
Fox Corp. is buying streaming giant Roku in a blockbuster deal valued at roughly $22 billion, including debt, creating a media powerhouse that the companies say will become the third-largest player in US television by share of viewing.
The acquisition, first reported by the Wall Street Journal, brings together Fox’s portfolio of live sports, news and entertainment programming with Roku’s streaming platform and connected-TV operating system, which reaches more than 100 million households worldwide.
Fox CEO Lachlan Murdoch touted the merger as a transformational move as competition for streaming audiences intensifies.
A Roku billboard in Times Square. ZUMAPRESS.com A person walks past the Fox News building in Midtown Manhattan. AP Photo/Yuki Iwamura The deal combines “the most valuable live content portfolio in video consumption with the preeminent streaming platform,” Murdoch told investors on a conference call on Monday.
Fox Corp is sister company to The Post’s corporate parent News Corp.
Shares of streaming pioneer Roku (ROKU +20.08%) jumped about 20% on Friday, touching their highest level in about four years, after Bloomberg reported that the company is in talks to sell itself. According to the report, Roku has held discussions with at least one unnamed U.S. media company about a potential combination, though no decisions have been made and there is no certainty the talks will lead anywhere. At one point during the session, the stock was up as much as 24%.
The chatter is easy to get excited about. A strategic buyer would be acquiring a platform that reaches more than 100 million streaming households, and the company's market value sits at about $21 billion as of this writing.
But a rumor is not a bid. And the takeover headline overshadowed a second catalyst behind Friday's move -- one that is already confirmed, and one that comes with a date: June 22.
Here's why that date may matter more than the deal talk.
Image source: The Motley Fool.
The catalyst on the calendar On June 5, S&P Dow Jones Indices said Roku will be added to the S&P MidCap 400 before the market opens on Monday, June 22, as part of the index provider's quarterly rebalance, joining under the index's communication services group.
That may sound like nothing more than housekeeping, but it leads to real buying. Index funds and exchange-traded funds that track the S&P MidCap 400 have to hold what the index holds, so once Roku is in, those funds need to buy the stock to match the benchmark. This kind of mechanical demand, therefore, is pretty much in the bag at this point -- and it shows up regardless of price or whether the sale talks go anywhere.
So, the reported deal discussions are preliminary and may not amount to anything. The index addition, by contrast, is a known, dated event.
Of course, this is a one-time wave of demand rather than a lasting change in the business's value. A business's performance will likely be the main driver of a stock's value over the long-term. So, I wouldn't count on this index inclusion as a guarantee that the stock will do well.
And it's worth noting that things can go sour after an inclusion, too. Consider The Trade Desk. Since its inclusion in the S&P 500 commenced on July 18 of last year, the stock has slid more than 75%.
What investors are actually buying The bigger question is arguably what sits beneath the index flows and the deal chatter. And here, the growth stock's recent results help the case.
In the first quarter of 2026, reported in late April, Roku's platform revenue (the advertising and subscriptions business that runs on top of its operating system) rose 28% year over year to $1.13 billion. That was an acceleration from 18% growth in the fourth quarter of 2025. Advertising climbed 27%, helped by a shift in how Roku sells its video advertising inventory.
"The majority of our video delivery is now through third-party programmatic partners, and we are growing quickly," said Roku Media President Charlie Collier during the company's first-quarter earnings call.
Additionally, subscriptions grew 30%, or about 23% excluding Roku's Frndly acquisition.
Just as notable is the company's swing in profitability. Roku posted net income of $86 million in the first quarter, reversing a loss in the same period a year earlier, and it has now been profitable in every quarter since the middle of 2025 after years of losses. And free cash flow over the trailing 12 months reached an all-time high, and management has said it expects to reach $1 billion in annual free cash flow by 2028, if not sooner.
But one part of the business continues to drag on results. Roku sells its players and TVs at or below cost to pull viewers onto the platform, and device revenue fell 16% in the quarter and carried a negative margin. Management also warned that tightening memory-chip supply could weigh on device margins in the second half of the year.
Today's Change
(
20.08
%) $
24.02
Current Price
$
143.66
So, what does all of this mean for Roku stock?
After Friday's pop, Roku trades at north of 100 times earnings, or about 60 times this year's expected earnings -- a rich valuation that is downright difficult to justify.
With this said, I do think the platform business is genuinely inflecting, and the 100 million streaming households it crossed in April give it the scale a media buyer might covet. But index buying is mechanical and temporary, and the deal talk may never materialize. Ultimately, neither is a reason to own Roku for the long haul. And with so much already priced in after the run-up, I'll be passing on Roku stock at this level, despite the buzz.
ToplineFox Corporation on Monday announced it reached an agreement to buy the streaming service Roku for $22 billion, expanding Fox’s streaming portfolio in a transaction the companies said would create the “third-largest player in U.S. television.”
The tie-up will create the “third-largest player in U.S. television,” the companies said.
Associated Press
Key FactsFox said it would acquire Roku for $160 per share in a deal the companies expect to include $400 million in savings.
Fox CEO Lachlan Murdoch, the eldest son of billionaire Rupert Murdoch, called the deal a “defining moment” for Fox that brings “together the most valuable live content portfolio and video consumption with the preeminent streaming platform through which America watches it.”
Paolo Pescator, an analyst for PP Foresight, told Reuters the transaction gives Fox “greater control over discovery, data and monetization” as TV viewing shifts to streaming.
Roku shareholders will receive $96 in cash and roughly 0.97 Fox Class A shares for each Roku share held, and Fox shareholders will own about 73% of the combined company after closing, the companies said.
Shares of Fox plunged by more than 11% in premarket trading, while Roku traded up slightly (0.8%).
forbes valuationRupert Murdoch—who stepped down as chairman of his Fox Corporation in September 2023—and his family have a fortune valued at $23.3 billion, according to Forbes’ estimates. Anthony Wood, who founded Roku in 2002, has an estimated net worth of $3.2 billion.
key backgroundA deal for Roku marks the first major acquisition since Lachlan Murdoch assumed Rupert Murdoch’s board seat in 2023. Fox, like other media giants, has shifted toward streaming in recent years: The company announced in 2020 it would buy the ad-supported streaming service Tubi for $440 million. In 2025, it launched the subscription livestreaming service Fox One, on which the FIFA World Cup has been forecast in recent days. Tubi reached profitability for the first time last year, announcing in July it reached more than 100 million monthly active users and 1 billion hours of streamed content per month. Netflix, in comparison, reported more than 300 million subscribers as of late 2024.
further readingForbesLachlan Murdoch Might Be Involved In TikTok Deal, Trump SaysBy Zachary Folk
On June 15, 2026, we delve into the DCF analysis for Amgen Inc AMGN , a company that has shown strong price performance over the past year, with a 23.1% increase. The stock has also performed well in the short term, gaining 1.6% over the past week and 6.4% over the past month.
DCF Earnings-based intrinsic value of $292.40 vs current price of $355.20 (margin of safety: -21.5%) DCF FCF-based intrinsic value of $183.01 vs current price (second opinion indicates modest overvaluation) GF Score™ of 87/100 suggests high reliability of the DCF inputs What Is AMGN Worth? DCF Earnings-Based Model The DCF earnings-based model for Amgen Inc AMGN utilizes a two-stage growth model to estimate the intrinsic value of the stock. In the first stage, we project earnings growth over the next ten years, followed by a terminal phase where growth stabilizes. The model assumes a current EPS of $22.10 and a growth rate of 7.1% for the first decade.
Parameter Value Current EPS (TTM, excl. non-recurring) $22.10 10-Year Growth Rate 7.1% 10-Year Treasury Rate 4.45% Discount Rate (ceil(Treasury) + 6%) 11% Terminal Growth Rate 4% In the growth phase (Years 1-10), the EPS is expected to grow at 7.1% per year, discounted at a rate of 11%. The calculated value for this stage is $182.49 per share. In the terminal phase (Years 11-20), growth is expected to slow to a terminal rate of 4%, also discounted at 11%, resulting in a value of $109.91 per share. The intrinsic value is then calculated by summing the growth stage value and the terminal stage value.
Stage Description Value Growth Stage (Years 1-10) EPS growing at 7.1%, discounted at 11% $182.49 Terminal Stage (Years 11-20) 4% terminal growth, discounted at 11% $109.91 Intrinsic Value Growth + Terminal $292.40 With the current price at $355.20, the intrinsic value of $292.40 indicates that the stock is fair valued, with a margin of safety of -21.5%. It is important to note that GuruFocus utilizes EPS excluding non-recurring items, as research shows that stock prices correlate more closely with earnings than with free cash flow. For further details, visit the AMGN DCF Calculator.
What Does the Free Cash Flow DCF Say? The free cash flow (FCF) based intrinsic value for Amgen Inc AMGN is calculated at $183.01. When comparing this to the earnings-based intrinsic value of $292.40, the two models present differing perspectives. The FCF model suggests that the stock is modestly overvalued, with a significant margin of safety of -94.1%.
How Does GF Value™ Compare to the DCF Models? The GF Value™ for Amgen Inc is calculated at $353.42, providing a third perspective on valuation. This proprietary measure from GuruFocus is derived from historical trading multiples, past business growth, and future performance estimates. The GF Value™ aligns closely with the current price, indicating that the stock is slightly overvalued. Overall, the three models present a mixed view on valuation, with the DCF earnings model suggesting fair value, the FCF model indicating modest overvaluation, and the GF Value™ suggesting slight overvaluation. For more information, visit the GF Value™ page.
What Does AMGN's GF Score™ Tell Us? The GF Score™ ranks stocks from 0 to 100 based on five key aspects: Financial Strength, Profitability, Growth, Valuation, and Momentum. Stocks with higher GF Score™ values have been found to generate higher long-term returns based on backtested data from 2006-2021. Amgen Inc has a GF Score™ of 87/100, indicating strong performance across these metrics.
Metric Rating GF Score™ 87/100 Financial Strength 4/10 Profitability 10/10 Growth 9/10 Valuation 9/10 Momentum 3/10 With a predictability rank of 4/5 stars, the DCF model is considered more reliable for Amgen Inc. For further insights, visit the AMGN stock page.
Key Assumptions and Limitations It is important to note that DCF models are highly sensitive to assumptions regarding growth rates and discount rates. Stocks with lower predictability ratings tend to produce less reliable DCF estimates. The terminal growth rate of 4% used in the model is a simplifying assumption that may not reflect actual future performance.
What This Means for Investors In synthesizing the three valuation models—DCF earnings, DCF FCF, and GF Value™—the consensus indicates that Amgen Inc is currently fair valued based on the earnings model, modestly overvalued according to the FCF model, and slightly overvalued according to the GF Value™. Overall, investors should approach with caution. For the full DCF analysis, visit the AMGN DCF Calculator. You can also explore the GF Value™ page, or use the GuruFocus Stock Screener to find undervalued predictable companies.
Frequently Asked Questions What is AMGN's intrinsic value based on DCF?
earnings-based $292.40, FCF-based $183.01
Is AMGN overvalued or undervalued?
Based on the DCF and GF Value™ consensus, AMGN appears to be slightly overvalued.
How reliable is the DCF model for AMGN?
With a predictability rank of 4/5, the DCF model is considered reliable for AMGN.
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].
The count of cities with $1 million starter homes has nearly tripled since 2020, an enduring sign of how the pandemic housing boom reset affordability for first-time buyers
The number of cities where a typical starter home is worth $1 million or more has nearly tripled since before the pandemic, rising from 80 in February 2020 to a record 242 today. California still has the most cities with million-dollar starter homes, but New York and New Jersey are seeing the fastest growth. Nationwide, the typical starter home is worth $198,649, up 1.7% from a year ago. , /PRNewswire/ -- The bar for entry-level homeownership has never been higher. While the typical starter home nationwide is worth $198,649, a record 242 cities now have starter homes valued at $1 million or more, according to a new Zillow® analysis.
A typical "starter home" is defined for this analysis as a home in the lowest third of home values in a given region. The count of cities with million-dollar starter homes has grown from 226 cities a year ago, even as affordability pressures have begun to ease in parts of the country.
A record 242 US cities now have starter homes that cost $1 million, according to Zillow The effects of the pandemic housing boom have proven durable. A housing shortage, a decade in the making, ran headlong into intense demand amid historic lows in mortgage rates, driving up home values at a record pace. While plenty of markets are still feeling the pinch of this price reset, conditions are slowly becoming friendlier for buyers: The typical home buyer now breaks even relative to renting after roughly six years, down from more than eight years in late 2023.
"The pandemic reset the cost of buying a home, spreading million-dollar starter homes from a handful of coastal states to more than two dozen states across the country," said Kara Ng, senior economist at Zillow. "But while it may feel like a market of beer tastes at champagne budgets, those million-dollar starter homes are still the exception. More inventory, slower price growth and a narrowing rent-versus-buy gap mean buyers who are financially prepared are generally in better shape than in recent years."
New York and New Jersey are the fastest-growing states on the list, adding 15 cities combined in the past year. New York's total has reached 41 — up from just 12 before the pandemic — while New Jersey's has grown to 26, up from only one. The pattern mirrors what Zillow found in its 2026 hottest markets analysis: Six of the 10 most competitive housing markets in the country are in the Northeast, where new construction has lagged and inventory deficits run deep.
"Million-dollar starter homes are popping up in more Northeast cities because the housing shortage there hasn't been solved," said Ng. "Sun Belt markets have responded with new supply and seen price growth moderate as a result. The Northeast hasn't had that relief. Eliminating barriers to building like restrictive zoning is the most direct path to improvement, which is something Zillow is actively advocating for across the country."
California still leads overall with 105 cities, and 26 states now have at least one city with million-dollar starter homes, up from nine before the pandemic. Before 2020, this list was made up almost entirely of coastal states; Colorado was the only interior state with a million-dollar starter home city. Now, Texas, Wyoming and Illinois, among others, have multiple such cities.
The New York City metro area, which includes parts of New Jersey and Pennsylvania, leads all metro areas with 63 cities where a typical starter home costs $1 million or more. The San Francisco metro follows with 37, then Los Angeles (33), San Jose (13), Miami (8) and Seattle (8).
For buyers navigating today's market, Zillow Home Loans' BuyAbility℠ tool provides a personalized, real-time estimate of the home price and monthly payment that fit within their budget. Home listings on Zillow also include a down payment assistance module to help shoppers identify local programs that may be available to them.
For those who decide renting is the right call, Zillow Rentals® lists options across every price point and property type — including single-family homes, apartments and individual room listings. Renters can also use CreditClimb to report on-time rent payments to the major credit bureaus, building the credit history that will put them in a stronger position when they're ready to buy.
State
Cities with $1M+
Starter Homes
(April 2026)
Cities with $1M+
Starter Homes
(April 2025)
Cities with $1M+
Starter Homes
(February 2020)
United States
242
226
80
California
105
106
52
New York
41
31
12
New Jersey
26
21
1
Florida
11
11
4
Massachusetts
10
10
1
Washington
8
8
7
Texas
7
6
0
Connecticut
4
4
0
Hawaii
4
5
1
Maryland
4
4
1
Colorado
3
3
1
South Carolina
3
2
0
Wyoming
2
2
0
Illinois
2
1
0
Pennsylvania
1
1
0
Arizona
1
1
0
Georgia
1
1
0
Kansas
1
1
0
Michigan
1
1
0
Minnesota
1
1
0
Missouri
1
1
0
New Hampshire
1
1
0
Nevada
1
1
0
Rhode Island
1
1
0
Utah
1
1
0
Virginia
1
1
0
About Zillow Group
Zillow Group, Inc. (Nasdaq: Z and ZG) is reimagining real estate to make home a reality for more and more people.
As the most visited real estate app and website in the United States, Zillow connects hundreds of millions of consumers with innovative technology, trusted agents and loan officers, and seamless digital solutions. With industry-leading tools and resources, Zillow supercharges real estate professionals so they can grow their businesses and deliver exceptional client experiences. For renters and housing providers, Zillow offers not only a robust marketplace but a set of end-to-end products and services to streamline applications, leases, payments and more.
Zillow's ecosystem spans the entire home journey — from dreaming and shopping to renting, buying, selling and financing.
Zillow Group's affiliates, subsidiaries and brands include Zillow®, Zillow Premier Agent®, Zillow Home Loans®, Zillow Rentals®, Zillow® New Construction, Trulia®, StreetEasy®, Out East®, HotPads®, Follow Up Boss®, ShowingTime®, dotloop® and Zillow® Closing.
Sea Limited remains a Strong Buy as robust Q1 results reinforce its position to capitalize on long-term macro tailwinds in high-growth regions. SE posted strong segment growth: Shopee GAAP revenue up 45.1% YoY, Monee loans up 71.3%, and Garena bookings up 20.1%, driving overall net income higher. Valuation remains attractive with a conservative SOTP approach yielding an intrinsic value of $130.11 per share, well above current levels.
Spin-off distribution is expected to occur on June 29, 2026 Honeywell Aerospace will be a leading global tier-1 aerospace and defense supplier of mission critical systems and technologies Honeywell Technologies will be a global leader of the industrial world's transition from automation to autonomy , /PRNewswire/ -- Honeywell (NASDAQ: HON) today announced that its Board of Directors has formally approved the planned spin-off of Honeywell Aerospace. This approval represents a significant milestone in the separation process, which remains on track for completion on June 29, 2026. Following the completion of the spin-off, the remaining pure-play automation company will be known as Honeywell Technologies.
At 12:01 a.m. New York City time on June 29, 2026 (the "Distribution Date"), Honeywell will distribute all of the issued and outstanding shares of Honeywell Aerospace common stock pro rata to Honeywell shareowners of record on June 15, 2026 (the "Record Date"), on the basis of one share of Honeywell Aerospace common stock for every two shares of Honeywell common stock held as of the close of business on the Record Date. The distribution is subject to the satisfaction or waiver of certain conditions, as set forth in the form of Separation and Distribution Agreement filed with the U.S. Securities and Exchange Commission ("SEC") as part of Honeywell Aerospace's registration statement on Form 10, which was declared effective by the SEC on June 11, 2026.
"Today's announcement clears the path to establishing two independent industry leaders in Honeywell Aerospace and Honeywell Technologies and also reflects our significant portfolio transformation over the past three years," said Vimal Kapur, Chairman and CEO of Honeywell. "With clear strategies and growth drivers that build on Honeywell's century-long legacy, we are confident that both companies will be well-positioned to maximize long-term value for customers, employees and shareowners."
Honeywell Aerospace common stock is expected to begin trading on the Nasdaq Stock Market LLC ("Nasdaq") under the ticker symbol "HONAV" on a "when-issued" basis on or about June 15, 2026. Honeywell Aerospace common stock is expected to begin "regular-way" trading on Nasdaq under the ticker symbol "HONA" on June 29, 2026. Following the separation, Honeywell Technologies will continue to trade on the Nasdaq under the ticker "HON."
Beginning on or about June 15, 2026 and continuing through June 26, 2026, it is expected that there will be two markets in Honeywell common stock onNasdaq: a "regular-way" market under Honeywell's current ticker symbol "HON", in which Honeywell shares will trade with the right to receive shares of Honeywell Aerospace common stock on the Distribution Date, and an "ex distribution" market under the ticker symbol "HONIV", in which Honeywell shares will trade without the right to receive shares of Honeywell Aerospace common stock on the Distribution Date.
As previously announced, a 1-for-2 reverse stock split of Honeywell Technologies common stock will immediately follow the spin-off along with a proportionate reduction in the Company's number of authorized shares of common stock, subject to and contingent on the completion of the Honeywell Aerospace spin-off.
About Honeywell
Honeywell is an integrated operating company serving a broad range of industries and geographies around the world, with a portfolio that is underpinned by our Honeywell Accelerator operating system and Honeywell Forge platform. As a trusted partner, we help organizations solve the world's toughest, most complex challenges, providing actionable solutions and innovations for aerospace, building automation, industrial automation, process automation, and process technology that help make the world smarter and safer as well as more sustainable.
Additional Information
Honeywell uses our Investor Relations website, www.honeywell.com/investor, as a means of disclosing information which may be of interest or material to our investors and for complying with disclosure obligations under Regulation FD. Accordingly, investors should monitor our Investor Relations website, in addition to following our press releases, SEC filings, public conference calls, webcasts, and social media.
Forward-Looking Statements
Certain statements in this release are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are those that address activities, events, or developments that management intends, expects, projects, believes, or anticipates will or may occur in the future. They are based on management's assumptions and assessments in light of past experience and trends, current economic and industry conditions, expected future developments, and other relevant factors, many of which are difficult to predict and outside of our control. They are not guarantees of future performance, and actual results, developments and business decisions may differ significantly from those envisaged by our forward-looking statements. We do not undertake to update or revise any of our forward-looking statements, except as required by applicable securities law. Our forward-looking statements are also subject to material risks and uncertainties, including ongoing macroeconomic and geopolitical risks, such as changes in or application of trade and tax laws and policies, including the impacts of tariffs and other trade barriers and restrictions, lower GDP growth or recession in the U.S. or globally, supply chain disruptions, capital markets volatility, inflation, and certain regional conflicts, that can affect our performance in both the near- and long-term. In addition, no assurance can be given that any plan, initiative, projection, goal, commitment, expectation, or prospect set forth in this release can or will be achieved. Some of the important factors that could cause Honeywell's actual results to differ materially from those projected in any such forward-looking statements include, but are not limited to: (i) the ability of Honeywell to effect the spin-off transaction described above and to meet the conditions related thereto; (ii) the possibility that the spin-off transaction will not be completed within the anticipated time period or at all; (iii) the possibility that the spin-off transaction will not achieve its intended benefits; (iv) the impact of the spin-off transaction on Honeywell's businesses and the risk that the spin-off transaction may be more difficult, time-consuming or costly than expected, including the impact on Honeywell's resources, systems, procedures and controls, diversion of management's attention and the impact and possible disruption of existing relationships with regulators, customers, suppliers, employees and other business counterparties; (v) the possibility of disruption, including disputes, litigation or unanticipated costs, in connection with the spin-off transaction; (vi) the uncertainty of the expected financial performance of Honeywell or Honeywell Aerospace following completion of the spin-off transaction; (vii) negative effects of the announcement or pendency of the spin-off transaction on the market price of Honeywell's securities and/or on the financial performance of Honeywell; (viii) the ability to achieve anticipated capital structures in connection with the spin-off transaction, including the future availability of credit and factors that may affect such availability; (ix) the ability to achieve anticipated tax treatments in connection with the spin-off transaction and future, if any, divestitures, mergers, acquisitions and other portfolio changes and the impact of changes in relevant tax and other laws; (x) the failure to realize expected benefits and effectively manage and achieve anticipated synergies and operational efficiencies in connection with the spin-off transaction and completed and future, if any, divestitures, mergers, acquisitions, and other portfolio management, productivity and infrastructure actions; and (xi) the possibility that the reverse stock split and authorized share reduction will not be completed within the anticipated time period or at all, including due to a failure of the spin-off transaction to occur. These forward-looking statements should be considered in light of the information included in this release, our Form 10-K and other filings with the SEC. Any forward-looking plans described herein are not final and may be modified or abandoned at any time.
Broadcom (NASDAQ:AVGO | AVGO Price Prediction) is in the middle of the most aggressive AI ramp in semiconductor history, yet shares trade nowhere near their 52-week high.
CEO Hock Tan told investors last quarter that “Broadcom achieved record revenue, operating profit and free cash flow in Q2 driven by accelerating growth in AI semiconductor revenue and strong operating leverage”, with AI chip sales jumping 143% year-over-year to $10.8 billion. The stock sits at $382.07. Can AVGO hit $550 by 2027?
What’s Holding Broadcom Back Despite the blowout Q2 earnings, AVGO is down 8.33% over the past month and off 0.95% on the week. The stock peaked at $495 on the earnings release day and has declined since. Two factors drive the pullback:
First, the bar got higher. With Q3 guidance calling for $29.4 billion in revenue and AI sales over 200% YoY, any slippage gets punished. Second, sentiment momentum is fading. The composite sentiment score has declined 14.98 points over 30 days, sliding from a May peak of 73.43 to 50.57 today. With a beta of 1.43, AVGO trades like the high-beta AI bellwether it is.
Wall Street Sees 37% Upside. Our Model Says That’s Light Of 48 analysts, 7 rate it Strong Buy, 37 Buy, and 4 Hold, with zero sells. The consensus target sits at $522.06. Our model lands at a base case of $494.32, implying 29.38% upside, with a bull case of $540.32 and a bear case of $411.57, all at 90% confidence.
The consensus target assumes only modest multiple expansion off forward earnings still being revised higher each quarter. Hock Tan has guided to “AI revenue from chips, just chips, in excess of $100 billion in 2027”. If that lands, $522 looks conservative.
The Path to $550 Per Share Reaching $550 from today’s price of $382.07 requires a gain of 44%. With forward EPS of $12, a price of $550 implies a forward P/E of 46x. Our base case of $494.32 already implies 47x, meaning the bold target requires zero additional multiple expansion. The entire gain comes from earnings growth alone.
That’s why $550 is in play. The catalyst stack is loaded. Apollo Global just led a $35 billion financing deal for Broadcom’s AI XPV Platform.
Tan disclosed six committed XPU customers including Google, Anthropic, Meta, and OpenAI, with OpenAI deploying “their first-generation XPU in volume in 2027 at over 1 gigawatt of compute capacity”. Capacity is locked through 2028. The primary risk is hyperscaler capex normalizing faster than expected.
Broadcom’s Valuation Today At $382.07 against $12 in forward EPS, AVGO trades at a forward multiple near 32x. For a business growing AI revenue over 140% with 68% adjusted EBITDA margins, it’s reasonable. Shares sit 23% below the 52-week high of $495 and well above the $242.78 low. The 10-year return of 2,996% shows what compounding earnings power looks like when AI tailwinds hit a Hock Tan operating model.
Is $550 Realistic? Reaching $550 requires a 44% gain from here. The math works without further multiple expansion if forward EPS estimates hold. Three things need to go right:
AI semiconductor revenue must track toward Tan’s $100 billion 2027 goal, the six XPU customers must convert into volume shipments on schedule, and gross margins must hold near 77% through the AI mix shift. A hyperscaler capex pause would derail it. We’ve outlined the blueprint for how Broadcom could reach $550 in 2027.
When you hear about artificial intelligence (AI) chips, your mind instantly shifts to Nvidia or maybe even Advanced Micro Devices. These are two rock-solid options, but there is another that I think should be top of mind: Broadcom (AVGO 0.85%), a major player in the AI chip industry, even if most people don't know anything about the company. Fortunately for investors, its stock is now on sale and looks to be a great opportunity.
Broadcom is now about 20% down from its all-time high, and with major chip demand coming in the next few years, its stock is sure to skyrocket back to new all-time highs.
Image source: Getty Images.
Broadcom is taking a different approach to AI chips Companies like Nvidia and AMD champion their graphics processing units (GPUs) to clients as the best chips for AI clusters. GPUs can handle a wide variety of inputs and are very flexible for the tasks assigned to them.
But many AI companies have their training and inference workflows streamlined to a very precise formula, so they don't need the flexibility of a GPU. In fact, most of its features are wasted. Instead, companies are starting to turn to companies like Broadcom to help them design application-specific integrated circuits (ASICs). They have been around for a long time and are deployed in a variety of settings, but their biggest use case yet will be AI computing.
Today's Change
(
-0.85
%) $
-3.27
Current Price
$
382.30
Broadcom helps its clients design and fabricate their custom chips, and the results have been incredible so far. The best example of a Broadcom-designed custom AI chip is the Tensor Processing Unit (TPU) from Alphabet. This chip has been so successful that Alphabet is selling it to external clients. Other core clients include OpenAI and Anthropic, whose custom AI chip production will really ramp up in 2027.
This will lead to huge growth, and Broadcom expects its AI semiconductor revenue to top $100 billion in fiscal year 2027. The semiconductor division is only one part of the company, and Wall Street analysts expect revenue to reach $172 billion by the end of fiscal 2027. Over the past 12 months, the company has generated $75 billion, so it's projected to more than double its revenue by the end of next year.
AVGO Revenue (TTM) data by YCharts; TTM = trailing 12 months.
With Broadcom going on sale and having a strong offering in the AI realm, it looks like a no-brainer buy after the sell-off. The stock doesn't do this often, and it's time for investors to take advantage of the weakness and buy the stock today.
Keithen Drury has positions in Alphabet, Broadcom, and Nvidia. The Motley Fool has positions in and recommends Advanced Micro Devices, Alphabet, Broadcom, and Nvidia. The Motley Fool has a disclosure policy.
National Waste & Recycling Association recognized two company drivers, an operator and a technician for outstanding safety, performance and service
, /PRNewswire/ -- Four employees of Republic Services, Inc. (NYSE: RSG) subsidiaries were recognized by the National Waste & Recycling Association (NWRA) as the industry's best during the NWRA's 2026 Annual Awards Gala on June 10 in Washington, D.C. They were honored for their outstanding performance records and contributions that enhanced overall safety and strengthened the image of the waste and recycling industry.
Dave Bombei of Cedar Rapids, Iowa, was named the NWRA Technician of the Year; Ausencio Carrera of Houston, Texas, was named the NWRA National Safety-Sensitive Driver of the Year; Kenny Gallegos of Phoenix, Arizona, was named the NWRA Operator of the Year; and Donato "Tito" Ponce, also of Phoenix, Arizona, was named the NWRA National Roll-Off Driver of the Year.
In honor of their NWRA recognition, Republic Services leaders presented Carrera and Ponce with keys to new company trucks personalized with their names and 2026 NWRA honors displayed on the side. Bombei also received a new maintenance truck, along with customized tools recognizing his achievement. Gallegos, a heavy equipment operator who recently retired after 33 years with the company, was recognized at his local site alongside peers to mark his achievement.
"Our frontline employees bring technical expertise and a safety mindset to their work every day," said Jon Vander Ark, president and chief executive officer. "Tito, Kenny, Ausencio and Dave represent the best-of-the-best of our team, and we congratulate them on their well-deserved recognition and unwavering commitment to safety."
The NWRA Driver and Operator of the Year awards recognize member drivers, heavy equipment operators and technicians who work safely and responsibly, maintain outstanding performance records and enhance the safety and public image of the recycling and waste industry.
Since 2006, Republic Services employees have consistently earned recognition across multiple NWRA award categories, highlighting the company's commitment to safety and operational excellence.
2026 Driver of the Year – Roll-Off: Donato "Tito" Ponce
Tito Ponce is a roll-off driver with more than 31 years of service, primarily supporting operations at Phoenix Sky Harbor International Airport. He has maintained an exceptional safety record with no preventable incidents or injuries in one of the most complex, high-security operating environments in the country. Ponce is a trusted resource for colleagues and is actively involved in his community.
2026 Driver of the Year – Safety-Sensitive: Ausencio Carrera
With 27 years in the recycling and waste industry, Ausencio Carrera began his career as a helper and advanced through multiple roles to become a residential driver in Houston. His dedication and reliability, combined with deep industry knowledge and hands-on experience, have earned him lasting relationships with both customers and coworkers. Carrera takes pride in his work, supports his team and enjoys time with his family outside of work.
2026 Operator of the Year: Kenny Gallegos
Kenny Gallegos dedicated 33 years to Republic Services, supporting landfill and transfer station operations across Arizona as a heavy equipment operator. Known for his reliability, he consistently supported site operations, emergency response efforts and team training. He was a trusted resource for both teammates and leadership, taking pride in maintaining safe, well-run sites and fostering a strong team culture. Since retiring in May, Kenny is enjoying more time with his family.
2026 Technician of the Year: Dave Bombei
With more than 38-years in the industry, Dave Bombei supports preventative maintenance and emergency repair operations across multiple recycling facilities in Iowa. Throughout his career, he has maintained an exceptional safety record with no preventable incidents or injuries. His commitment to safety, team development and customer support has made him a trusted resource for colleagues. Outside of work, Dave values time with his wife of 37 years, his children and grandchildren, and enjoys spending time outdoors.
About Republic Services
Republic Services, Inc. is a leader in the environmental services industry. Through its subsidiaries, the company provides customers with the most complete set of products and services, including recycling, solid waste, special waste, hazardous waste and field services. Republic's industry-leading commitments to advance circularity and support decarbonization are helping deliver on its vision to partner with customers to create a more sustainable world. For more information, please visit RepublicServices.com.
Republic Services Media Relations
[email protected]
(480) 757-9770
SPRINGDALE, Ark., June 15, 2026 (GLOBE NEWSWIRE) -- Hillshire ReserveTM brand is redefining lunchmeat, introducing a new line designed to elevate how it’s enjoyed across the day. With bold flavors, premium ingredients and meats naturally smoked over real hardwood, Hillshire Reserve lunchmeat brings a more refined approach to a familiar category.
From quick lunches to shareable boards, the line expands how lunchmeat fits into everyday routines and more intentional moments at home. Offering a range of varieties for different tastes and occasions, the Hillshire Reserve lunchmeat lineup has options that feel both thoughtfully crafted and simple to use.
Available varieties include:
Applewood Smoked HamApplewood Smoked Turkey BreastMesquite Smoked Chicken BreastHerb Smoked Turkey BreastSmoked Maple Ham Made with all-natural ingredients and no artificial preservatives, each product delivers 11–13 grams of protein per serving. Whether layered, paired or served on its own, Hillshire Reserve lunchmeat is designed to bring quality and flavor to the way people eat today.
As expectations for everyday foods continue to rise, Hillshire Reserve lunchmeat meets consumers with options that deliver flavor, simplicity and versatility, bringing a fresh perspective to the category.
Hillshire Reserve lunchmeat is now available at select retailers nationwide.
The Hillshire Reserve brand is owned by a subsidiary of Tyson Foods.
About Tyson Foods, Inc.
Tyson Foods, Inc. (NYSE: TSN) is a world-class food company and recognized leader in protein. Founded in 1935 by John W. Tyson, it has grown under four generations of family leadership. The Company is unified by this purpose: Tyson Foods. We Feed the World Like Family™ and has a broad portfolio of iconic products and brands including Tyson®, Jimmy Dean®, Hillshire Farm®, Ball Park®, Wright®, State Fair®, aidells® and ibp®. Tyson Foods is dedicated to bringing high-quality food to every table in the world, safely and affordably, now and for future generations. Headquartered in Springdale, Arkansas, the Company is a member of the S&P 500 and Russell 1000 large capitalization indices. It had approximately 133,000 team members on September 27, 2025. Visit www.tysonfoods.com.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/91d3961e-b8af-4fde-92bd-edea9b54ff20
Alexandria ranked 16th among all S&P 500 companies and was the highest-ranked equity
REIT in the talent readiness category, which places it among an elite group of companies
distinguished by their ability to cultivate highly engaged workforces, develop strong leaders
and create workplace environments built for enduring success
, /PRNewswire/ -- Alexandria Real Estate Equities, Inc. (NYSE: ARE), the first, preeminent, longest-tenured and pioneering owner, operator and developer of collaborative Megacampus™ ecosystems in AAA life science innovation and advanced technology clusters, today announced that it has been recognized by The Wall Street Journal Leadership Institute and Bendable Labs as one of the nation's leading companies positioned for future success, ranking 16th in talent readiness among all S&P 500 companies in the inaugural "Best Companies for the Future" list. Alexandria was also the highest-ranked equity REIT in the category, reflecting the strength of its people-first culture and its differentiated, multifaceted approach to attracting, developing and retaining exceptional egoless talent.
The Wall Street Journal's "Best Companies for the Future" ranking evaluates S&P 500 companies across six dimensions considered critical for long-term performance: AI readiness, innovation, talent readiness, financial fitness, resilience and agility. The talent readiness category measures a company's ability to attract talent, develop talent and leadership, retain employees, build highly engaged workforces, create workplace environments where employees can thrive and continue at a high level and position the organization for long-term success through its people strategy.
"Alexandria has built a leadership culture infused with the personal humility to continually learn, combined with the professional will to do whatever it takes to enhance the success of its customers, and through them, change the world through innovation," remarked Jim Collins, world-renowned business strategist and best-selling author. In today's challenging and changing landscape, Alexandria's steadfast commitment to its mission and its best-in-class team's relentless attention to detail in its continual pursuit of operational excellence reinforces the company's consequential and enduring dedication to the industry.
For more than three decades, Alexandria has built a distinctive culture defined by entrepreneurial thinking, intellectual curiosity, disciplined execution and long-term stewardship. The company's culture of idea meritocracy encourages employees at all levels to contribute bold ideas and diverse perspectives, creating an environment where collaboration drives stronger outcomes for the company, its tenants, its investors and all stakeholders. Alexandria recognizes that its fundamental strength is powered by the contributions of every team member and that its future growth depends on their continued success. The company has made substantial and sustained investments in hiring, developing and retaining talented employees and has built an exceptional track record of long-tenured leadership and internal advancement. Alexandria's executive management team alone averages 15 years of experience with the company. This strong retention supports business continuity, reinforces the stability of Alexandria's leadership and reflects a meaningful depth of experience and expertise across its best-in-class team.
"People, passion and purpose are the driving forces behind Alexandria's mission-critical work to advance human health, and our team members are the foundation of our long-term success. This recognition is particularly meaningful because it reflects the enduring strength of our culture and the extraordinary people who bring our mission to life every day," said Madeleine Thorp, executive vice president – talent management at Alexandria Real Estate Equities, Inc. "We have intentionally cultivated a dynamic, high-performance environment rooted in excellence, collaboration, continuous learning and a deeply held belief in the power of idea meritocracy. By empowering talented individuals to bring forward their best ideas, challenge conventional thinking and contribute meaningfully, we continue to foster a workplace where exceptional people can grow, lead and make a consequential impact."
The company's commitment to talent development is reflected in robust investments in leadership development, professional growth, employee engagement, mentoring and wellness. Alexandria strives to create an open, respectful and empowering environment where employees can actively contribute, grow and realize their full potential through multifaceted opportunities and resources, including a variety of development programs. Alexandria also provides a comprehensive benefits package designed to meet and exceed the needs of its employees and their families, including a top-tier medical plan with 100% company-paid premiums and a truly unique offering, Alexandria Lifeline™, that extends Alexandria's world-class life science and healthcare ecosystem to provide access to highly specialized medical care for employees and their immediate family members facing serious illness or injury.
About Alexandria Real Estate Equities, Inc.
Alexandria Real Estate Equities, Inc. (NYSE: ARE), an S&P 500® company, is a best-in-class, mission-driven life science REIT making a positive and lasting impact on the world. With our founding in 1994, Alexandria pioneered the life science real estate niche. Alexandria is the preeminent and longest-tenured owner, operator, and developer of collaborative Megacampus™ ecosystems in AAA life science innovation cluster locations, including Greater Boston, the San Francisco Bay Area, San Diego, Seattle, Maryland, Research Triangle, and New York City. As of March 31, 2026, Alexandria has a total market capitalization of $20.44 billion and an asset base in North America that includes 35.8 million RSF of operating properties. Alexandria has a long-standing and proven track record of developing Class A/A+ properties clustered in highly dynamic and collaborative Megacampus environments that enhance our tenants' ability to successfully recruit and retain world-class talent and inspire productivity, efficiency, creativity, and success. Alexandria also provides strategic capital to transformative life science companies through our venture capital platform. We believe our unique business model and diligent underwriting ensure a high-quality and diverse tenant base that results in higher occupancy levels, longer lease terms, higher rental income, higher returns, and greater long-term asset value. For more information on Alexandria, please visit www.are.com.
Forward-Looking Statements
This press release includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements include, without limitation, statements regarding Alexandria's talent recruitment strategy, culture, employee development, and workplace environment; Alexandria's ability to attract, develop and retain exceptional talent and leadership; and the potential impact of Alexandria's talent-related initiatives, practices and investments on Alexandria's business, long-term growth and success. These forward-looking statements are based on Alexandria's present intent, beliefs, or expectations, but forward-looking statements are not guaranteed to occur and may not occur. Actual results may differ materially from those contained in or implied by Alexandria's forward-looking statements as a result of a variety of factors, including, without limitation, the risks and uncertainties detailed in its filings with the Securities and Exchange Commission. All forward-looking statements are made as of the date of this press release, and Alexandria assumes no obligation to update this information. For more discussion relating to risks and uncertainties that could cause actual results to differ materially from those anticipated in Alexandria's forward-looking statements, and risks and uncertainties to Alexandria's business in general, please refer to Alexandria's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and any subsequently filed quarterly reports on Form 10-Q.
CONTACT: Sara Cohen, Assistant Vice President – Corporate Strategy Events, (646) 799-2617, [email protected]
1. Futures Jump as U.S.-Iran Truce Announced Stock futures jumped after news broke of an agreement between the U.S. and Iran to end their conflict in the Middle East, set to be signed on Friday, leading to the opening of the Strait of Hormuz and the free flow of oil. In pre-market trading, S&P 500 futures rose around 1.2%, with Nasdaq futures gaining more than 2%. Oil prices quickly fell, with benchmark WTI crude below $81 per barrel early this morning.
Late recovery leaves stock market flat: Despite dips early in the week, ahead of the excitement of Friday's SpaceX (SPCX +19.17%) IPO, the S&P 500 ended the week up 0.65% with the Nasdaq up 0.70%. First challenge for new Fed head: The Fed's meeting to set interest rates takes place today – the first under new chair Kevin Warsh. The CME FedWatch tool shows a 96.6% probability of no change, with a greater than 50% chance of a rate rise by the end of the year. 2. Paramount Gets the Green Light The Department of Justice announced its approval of the Paramount Skydance (PSKY 0.19%) takeover of Warner Bros. (WBD +0.45%) Friday afternoon. The deal would end a long-standing Hollywood rivalry, giving Paramount control of media outlets including CNN and HBO Max – with the latter to combine with Paramount+ to reach around 200 million subscribers. Paramount stock gained over 4% in pre-market trading, with Warner largely unchanged.
"The transaction is not likely to result in harm to competition or American consumers": The Antitrust Division has not announced requirements for any divestitures, clearing the way for a merger that's raised political concerns – Paramount CEO David Ellison's father Larry is a major donor to President Trump. "Fewer opportunities for creators, fewer jobs ..., higher costs, and less choice": An open letter signed by over 1,400 actors, directors, and filmmakers had opposed the takeover, and California's Attorney General Rob Bonta has yet to decide whether to try to block the deal. Rocket Lab (RKLB 10.91%) shares fell by 12% Friday, the first day of trading for SpaceX, with Firefly Aerospace (FLY 19.05%) down 19%, Redwire (RDW 11.76%) down 11%, and AST SpaceMobile (ASTS 15.53%) down 15%. It would be pretty easy to conclude that the moves were related to SpaceX, with Elon Musk's $2 trillion space giant pulling capital away from smaller space names.
The best advice is not to get caught up in near-term volatility, but to focus on the quality of the individual businesses.
Investors in space companies need to buckle up. These are highly valued stocks in the early stages of their growth trajectory. We shouldn't be surprised if any or all of these stocks – SpaceX included – lose half their value or more in the quarters to come, even if they turn out to be fabulously successful investments.
So it is when investing in companies attempting to boldly go where no one has ever gone before.
4. This Week's Key Earnings to Watch: KMX, ACN, and KR CarMax (KMX 0.50%) is due to release first-quarter earnings for fiscal 2027 Wednesday, following a 47% fall in non-GAAP EPS year over year (YoY) in the final quarter of 2026 – as sales remained sluggish in the competitive used car market, and management raised its cost reductions target. Accenture (ACN +1.43%) will post Q3 results Thursday, after TMF chief investment officer Andy Cross noted "the challenges the world's largest digital consulting firm is facing" – with only a 1% rise in Q2 bookings in local currencies. Accenture is recommended by both Team Hidden Gems and Team Rule Breakers. Kroger (KR +0.92%), recommended in Dividend Investor, reports Q1 Thursday. Digital sales helped the retail giant grow profit 37% YoY in its previous quarter, though management expects comparable sales growth of only 1-2% in the current year. Kroger has raised its dividend for 20 consecutive years. 5. Your Take What's a region or international market you're watching, and why?
Discuss with friends and family, or become a member to hear what your fellow Fools are saying!
This image and article was created using Large Language Models (LLMs) based on The Motley Fool's insights and investing approach. It has been reviewed by our AI quality control systems. Since LLMs cannot (currently) own stocks, it has no positions in any of the stocks mentioned. The Motley Fool has positions in and recommends AST SpaceMobile, Accenture Plc, CarMax, Rocket Lab, and Warner Bros. Discovery. The Motley Fool recommends Kroger and recommends the following options: long January 2028 $260 calls on Accenture Plc and short January 2028 $280 calls on Accenture Plc. The Motley Fool has a disclosure policy.
SAN DIEGO, June 15, 2026 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Roblox Corporation (NYSE: RBLX) common stock between October 30, 2025 and April 30, 2026, both dates inclusive (the “Class Period”), have until August 7, 2026 to seek appointment as lead plaintiff of the Roblox class action lawsuit. Captioned Mukherjee v. Roblox Corporation, No. 26-cv-05489 (N.D. Cal.), the Roblox class action lawsuit charges Roblox as well as certain of Roblox’ top executive officers with violations of the Securities Exchange Act of 1934.
If you suffered substantial losses and wish to serve as lead plaintiff of the Roblox class action lawsuit, please provide your information here:
You can also contact attorneys Ken Dolitsky or Michael Albert of Robbins Geller by calling 800/851-7783 or via e-mail at [email protected].
CASE ALLEGATIONS: Roblox operates as a global video gaming and social networking company.
The Roblox class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) defendants created the false impression that they possessed reliable information pertaining to Roblox’ bookings growth expectations and the overall anticipated impact from the age verification rollout while also minimizing risks associated with the rollout and its potential knock-on effects; (ii) Roblox misled investors when discussing tailwinds resulting from the age verification process while continuing to be “enormously bullish” on their tech rollouts as well as claiming to be able to “rely on [their] tremendous organic growth”; and (iii) Roblox relied far too heavily on viral events to drive growth and failed to communicate to investors the potential knock-on impacts of the age verification rollout, including how it could impact the platform’s ratings, engagement, and overall public perception.
On April 30, 2026, Roblox announced its 2026 first quarter results, allegedly reporting declines in revenue guidance and projected annual bookings growth, as well as reductions in communication engagement, app store ratings, and organic sign-ups as a result of the age verification rollout. On this news, the price of Roblox stock fell more than 18%, according to the complaint.
THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Roblox common stock during the Class Period to seek appointment as lead plaintiff in the Roblox class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Roblox class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Roblox class action lawsuit. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Roblox class action lawsuit.
ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world’s leading law firms representing investors in securities fraud and shareholder rights litigation. Our Firm ranked #1 on the most recent ISS Securities Class Action Services Top 50 Report, recovering more than $916 million for investors in 2025. This marks our fourth #1 ranking in the past five years. And in those five years alone, Robbins Geller recovered $8.4 billion for investors – $3.4 billion more than any other law firm. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs’ firms in the world, and the Firm’s attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information:
Why: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Roblox Corporation (NYSE: RBLX) between October 30, 2025 and April 30, 2026, inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 7, 2026.
So what: If you purchased Roblox common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
What to do next: To join the Roblox class action, go to https://rosenlegal.com/cases/roblox-corporation-2026/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 7, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.
Details of the case: According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Roblox's organic growth potential; notably, that Roblox would see a significant slowdown in its growth rates as enrollment in the age verification rollout would quickly taper, compounding the resulting slowdown in on-platform communication, resulting in app store rating reductions and a swift reduction in organic growth. When the true details entered the market, the lawsuit claims that investors suffered damages.
To join the Roblox class action, go to https://rosenlegal.com/cases/roblox-corporation-2026/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com
Stock splits can create a lot of excitement among investors, so even though they do nothing to change the fundamental value of the underlying company, anticipation of such financial events can sometimes result in a stock booking some solid short-term gains. However, long-term investors also get excited about stock splits, because there's usually only one condition under which they occur: The stock had already risen to a level where management felt compelled to split it.
Gains like that indicate a strong investment -- and Wall Street's latest stock-split stock has provided investors with some great returns since its initial public offering.
CrowdStrike (CRWD 1.27%) debuted on the public markets back in 2019, and if you purchased the stock on its first trading day and held on, you're up over 1,000% on your investment. That's a fantastic return in just about seven years of trading, and many investors would be thrilled with that. As a result of its share price gains, it's enacting a 4-for-1 stock split at the start of July. But is there room for more growth?
Image source: Getty Images.
CrowdStrike's cybersecurity offering is best-in-class CrowdStrike offers all sorts of cybersecurity products, starting with endpoint protection. This is the base capability of its software, and helps protect network endpoints from bad actors. On top of that, CrowdStrike offers 33 other modules, ranging from artificial intelligence (AI) agents to cloud security to threat hunting. Overall, the company believes that these markets offer a cumulative $149 billion market opportunity.
Today's Change
(
-1.27
%) $
-8.80
Current Price
$
682.73
But that's just the start. Generative AI isn't just being used by businesses to improve efficiency; it's also being used to identify and exploit vulnerabilities, making top-notch cybersecurity software a must-have for all businesses. As a result, the cybersecurity market is expected to rapidly expand over the next few years, leading to a $325 billion market opportunity by 2030. That leaves plenty of room for CrowdStrike to expand, which it is doing a great job of right now.
CrowdStrike likes to focus on its annual recurring revenue figure over its total revenue because that paints a better picture of how its subscription business is expanding. In the first quarter, it rose 24% year over year to $5.51 billion. That's a solid growth rate, and CrowdStrike should be able to grow at a high double-digit pace for some time due to huge cybersecurity demand. This could lead to future success, but there is one more thing investors need to watch out for: profits.
CRWD Profit Margin (Quarterly) data by YCharts.
CrowdStrike's profitability over the past few years has been poor at best. A large part of that is a result of its prodigious stock-based compensation program. In Q1, it distributed over $317 million in stock-based compensation. That's about 23% of CrowdStrike's total revenue, and that has a significant impact on CrowdStrike's bottom line. It's barely profitable.
If CrowdStrike can start to increase its profitability over the next few years, then I have confidence that it's a great stock to buy right now, even before the stock split. However, if it doesn't start to turn the profitability corner, further market-crushing returns may be harder to come by.
The DOJ ApprovalWhat the Merger CreatesWhat’s Still Standing in the WayParamount Shares SpikePSKY Price Action: At the time of publication, Paramount shares are trading 2.18% higher at $10.70, according to data from Benzinga Pro.
Image via Shutterstock
This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Market News and Data brought to you by Benzinga APIs
Curated marketplace connects energy professionals, developers and partners to discover, deploy and scale trusted AI agents, domain models and digital applications
HOUSTON--(BUSINESS WIRE)--Global energy technology company SLB (NYSE: SLB) today announced the launch of the SLB Digital Marketplace, a curated digital destination designed to help energy companies rapidly discover and deploy specialized AI agents, domain models, skills, tools, data connectors and digital applications within their existing digital environments.
The SLB Digital Marketplace extends the company’s open platform strategy to its Tela™ agentic AI assistant by enabling SLB, partners, independent software vendors (ISVs), developers and customers to bring purpose-built digital capabilities to the energy industry through a single, governed channel. All marketplace offerings are certified against SLB standards for security, interoperability and compatibility before listing.
The launch comes as the industry moves toward agentic AI — where software can reason, act and automate across complex technical workflows. As these capabilities proliferate, energy companies will need access to a broader ecosystem of specialized tools that work together across planning, operations, data and AI.
“AI in energy is shifting from promise to performance,” said Olivier Le Peuch, chief executive officer of SLB. “The SLB Digital Marketplace is designed to accelerate that shift by creating an open ecosystem where innovation can scale, solutions can interoperate and customers can move faster from insight to action. This is how we translate AI into real performance across the energy system.”
“No single company can build every agent, model or application the energy industry will need,” said Rakesh Jaggi, president of SLB’s digital business. “The SLB Digital Marketplace is the next expression of our commitment to openness, giving energy professionals more choice while maintaining the governance and quality standards required for enterprise operations.”
The marketplace includes approximately 200 digital products including existing Ocean™ store solutions and new solutions from SLB and over 30 partners. These products span Delfi™ and Lumi™ SaaS applications, plug-ins, workflow extensions, data connectors, and Tela AI skills, agents and foundation models.
For energy professionals, the marketplace provides a single destination to evaluate and access trusted digital capabilities that extend workflows across the Delfi and Lumi environments. For developers, partners and ISVs, it provides a structured path to publish and scale solutions across the SLB ecosystem.
Developers and ISVs interested in listing applications can apply through the SLB partner program at marketplace.digital.slb.com and access additional developer resources at developer.slb.com.
Key Points:
SLB has launched the SLB Digital Marketplace, a curated destination to help energy companies rapidly discover and deploy AI and digital solutions within existing digital environments. The marketplace extends SLB’s open platform strategy, enabling SLB, partners, ISVs, developers and customers to deliver offerings through a single, governed channel certified for security, interoperability and compatibility. The launch addresses the industry shift toward agentic AI, where software can reason, act and automate across complex technical workflows. The marketplace includes approximately 200 digital products including existing Ocean™ store solutions and new solutions from SLB and over 30 partners. These products span Delfi™ and Lumi™ SaaS applications, plug-ins, workflow extensions, data connectors, and Tela AI skills, agents and foundation models. About SLB
SLB (NYSE: SLB) is a global technology company that has driven energy innovation for 100 years. With a global footprint in more than 100 countries and employees representing almost twice as many nationalities, we work each day on innovating oil and gas, delivering digital at scale, decarbonizing industries, and developing and scaling new energy systems that accelerate the energy transition. Find out more at slb.com.
This press release contains “forward-looking statements” within the meaning of the U.S. federal securities laws — that is, statements about the future, not about past events. Such statements often contain words such as “expect,” “may,” “can,” “estimate,” “intend,” “anticipate,” “will,” “potential,” “projected" and other similar words. Forward-looking statements address matters that are, to varying degrees, uncertain, such as forecasts or expectations regarding the deployment of, or anticipated benefits of, SLB’s new technologies and partnerships; statements about goals, plans and projections with respect to sustainability and environmental matters; forecasts or expectations regarding energy transition and global climate change; and improvements in operating procedures and technology. These statements are subject to risks and uncertainties, including, but not limited to, the inability to achieve net-negative carbon emissions goals; the inability to recognize intended benefits of SLB’s strategies, initiatives or partnerships; legislative and regulatory initiatives addressing environmental concerns, including initiatives addressing the impact of global climate change; the timing or receipt of regulatory approvals and permits; and other risks and uncertainties detailed in SLB’s most recent Forms 10-K, 10-Q and 8-K filed with or furnished to the U.S. Securities and Exchange Commission. If one or more of these or other risks or uncertainties materialize (or the consequences of such a development changes), or should underlying assumptions prove incorrect, actual outcomes may vary materially from those reflected in our forward-looking statements. The forward-looking statements speak only as of the date of this press release, and SLB disclaims any intention or obligation to update publicly or revise such statements, whether as a result of new information, future events or otherwise.
Corning GLW said it signed a multibillion-dollar, multidecade agreement with Amazon AMZN to expand domestic production of fiber-optic products used in data centers, according to a Sunday company update.
The deal is aimed at supporting growing infrastructure needs tied to artificial intelligence workloads, which require faster data transmission and higher network capacity inside large-scale data centers. Corning said the investment will increase U.S. manufacturing capacity for optical connectivity products.
The project is expected to create about 1,000 new jobs in North Carolina, in addition to construction-related employment and workforce training initiatives. Corning said the expansion will strengthen its domestic supply chain while helping meet rising demand from cloud and AI customers.
Industry observers view the agreement as another sign that major technology companies are increasing spending on the networking and optical infrastructure needed to support next-generation AI systems. Fiber-optic technology plays a key role in connecting servers and moving large volumes of data within modern data centers.
Users can now generate Wix Harmony websites directly within Microsoft 365 Copilot without context switching
NEW YORK - Wix (Nasdaq: WIX) Wix today announced its collaboration with Microsoft to bring Wix Harmony website creation into Microsoft 365 Copilot. Anyone can now create and access Wix Harmony directly via Copilot's generally available support for the Open AI Apps SDK, meeting users where they’re already working. The integration also gives access to the entire Wix ecosystem to enable entrepreneurs and businesses to not only launch a digital presence but also manage business logic and analyze performance directly within the Microsoft 365 interface, turning a chat window into a powerful engine for growth.
Within Microsoft 365 Copilot, users can simply describe the website they want via voice or text, detailing their business, goals and brand style. Then a complete, production-ready Wix Harmony website will be generated on Wix's enterprise-grade infrastructure, with built-in capabilities for commerce, scheduling, payments, SEO and GEO, accessibility, performance, security, and more. Users can then continue the workflow in the same conversation to add relevant business capabilities, analyze performance and implement changes through natural language.
“Wix Harmony enables anyone to optimize their digital experience and turn ideas into reality,” said Shahar Talmi, GM of Developer Platform at Wix. “With this collaboration, users can now also build within Microsoft 365 Copilot, eliminating the need to jump between tools. As creation moves into chat-based interfaces, Wix Harmony ensures that building a professional website is as simple and intuitive as asking for it in the platform you’re already on.”
"Bringing the Wix Harmony website creation experience into Microsoft 365 Copilot reflects where work is headed,” said Bryan Goode, CVP of Business Applications and Agents at Microsoft. "Through an interactive, chat‑based experience, teams can design, build, and manage sites directly in the flow of their work. Our goal is to make it easy to create and move work forward while reducing toggling and context switching as much as possible.”
To begin, connect the Wix app, then simply prompt “@Wix” in the chat. The website can be accessed and managed directly from Microsoft 365 Copilot or through the Wix Business Manager. Users can manage inventory, get analytics, update product pricing, manage their bookings, and more.
The Wix app is available to Microsoft 365 Copilot users in supported markets.
About Wix.com Ltd.
Wix’s vision is to simplify complex technologies and deliver the best tools for every type of user and business to create online. Powered by advanced AI and enterprise-grade infrastructure, Wix is trusted by millions of users worldwide. Founded in 2006 and strengthened by the acquisition in 2025 of Base44, the no-code application platform, Wix is continuing to build for the future of the internet.
Wix Partners with Microsoft 365 Copilot to Bring Website Creation into the Flow of Work
Wix Partners with Microsoft 365 Copilot to Bring Website Creation into the Flow of Work Users can now generate Wix Harmony websites directly within Microsoft 365 Copilot without context sw...
SOUTH SAN FRANCISCO, Calif., June 15, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform, today announced that members of its management team will participate in two upcoming events surrounding the BIO International Convention, taking place June 22-25, 2026, at the San Diego Convention Center in San Diego, CA.
2026 Taiwan Biotech Forum
Date: Sunday, June 21, 2026
Location: The Westin San Diego Gaslamp Quarter
Time: 1:30pm – 5:30pm PT
Sean Tucker, Ph.D., Chief Scientific Officer, will participate in a panel discussing innovative therapeutic modalities in precision medicine.
2026 BIO International Convention
Date: Tuesday, June 23, 2026
Location: San Diego Convention Center, Storytelling Stage (Booth #3035)
Time: 3:15pm – 3:35pm PT
Steve Lo, Chief Executive Officer, and Dr. Tucker will present on the innovation, development and consumer friendly approach of the company’s oral vaccine tablet platform. The discussion will highlight how targeting mucosal immunity via an oral pill could eliminate reliance on traditional needle injections and cold-chain logistics, offering a modern solution to improve global health equity and pandemic readiness.
About Vaxart
Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the Company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s development programs currently include pill vaccines designed to protect against coronavirus, norovirus, and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.
Contact
Vaxart Media and Investor Relations:
FINN Partners [email protected]
June 15, 2026 09:00 ET | Source: iHerb Holdings, Inc.
IRVINE, Calif., June 15, 2026 (GLOBE NEWSWIRE) -- iHerb CEO Emun Zabihi was named an EY US Entrepreneur Of The Year® 2026 Pacific Southwest Award winner. Zabihi was selected among nearly 1,000 program participants that included 592 finalists across 17 regions competing for the title.
Since becoming CEO in 2021, Zabihi has led iHerb through a period of significant international expansion and innovation. Today, iHerb serves millions of customers worldwide through a sophisticated global eCommerce and fulfillment network built on product authenticity, transparency and customer trust. Under Zabihi's leadership, the company has strengthened its position as a global wellness eCommerce platform dedicated to helping consumers access high-quality health and wellness products wherever they live.
“This recognition is a testament to the remarkable team members who bring our mission to life every day,” said Zabihi. “As consumer demand for health and wellness continues to grow globally, we remain focused on innovation, customer trust and delivering exceptional experiences that help people live healthy lives.”
Now in its 41st year, the Entrepreneur Of The Year program honors business leaders for their ingenuity, courage and entrepreneurial spirit. It celebrates original founders who bootstrapped their business from inception or raised outside capital to grow their company, transformational CEOs who infused innovation into an existing organization to catapult its trajectory and multigenerational family business leaders who reimagined a legacy business model to strengthen it for the future.
Regional winners were chosen by an independent panel of past winners, top CEOs and business leaders. Judges assessed candidates on long-term value creation, entrepreneurial spirit, purpose-driven commitment, and significant growth and impact.
As a Pacific Southwest award winner, Zabihi will now be considered by the national judges for the Entrepreneur Of The Year 2026 National Awards, which will be presented in November at the annual Strategic Growth Forum®, where high-growth CEOs, Fortune 1000 executives and investors converge to shape the future of business.
About Entrepreneur Of The Year
Founded in 1986, Entrepreneur Of The Year® has celebrated more than 11,000 ambitious visionaries who are leading successful, dynamic businesses in the US, and it has since expanded to nearly 60 countries and territories globally.
About iHerb, LLC
iHerb is one of the world's largest eCommerce retailers specializing in health and wellness, delivering products from approximately 2,000 brands to over 15 million active customers across 180 countries. Supported by a global workforce of nearly 2,000 team members, iHerb combines global scale with a deeply localized experience, offering service in 36 languages, over 80 currencies, and more than 40 local payment methods. iHerb's sophisticated global supply chain network spans nine climate-controlled fulfillment centers located in the U.S., Asia and the Middle East, providing customers a seamless and reliable shopping experience. Founded in 1996 and based in Irvine, California, iHerb is on a mission to make health and wellness accessible to all. For more information, please visit corporate.iherb.com.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/68f38e01-d020-42d8-8a40-76c68932ad8c
Emun Zabihi, CEO of iHerb iHerb CEO Emun Zabihi was awarded as a 2026 EY Entrepreneur of the Year winner for the Pacific South...
This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com.
Airlines
United Stock Surges but Airlines Are Not the Biggest Risers in the Iran Deal Rally
In this article
Airline stocks have often been the biggest movers—one way or the other—following the big moments in the Iran war. But that’s not the case on Monday.
NOT FOR DISSEMINATION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES OF AMERICA
TORONTO--(BUSINESS WIRE)--CI Global Asset Management (“CI GAM”) announces the following regular cash distributions for the CI ETFs for the month or quarter ending June 30, 2026. In all cases, the distribution will be paid on or before June 30, 2026 to unitholders of record on June 24, 2026. The ex-dividend date for all ETFs is June 24, 2026.
All CI ETFs trade on the Toronto Stock Exchange with the exception of the following, which trade on Cboe Canada: CI Canadian Equity ETF (CCDN); CI MSCI World ESG Impact Index ETF (CESG, CESG.B); CI Global Short-Term Bond Fund (ETF Series, CGSB); CI Global Healthcare Leaders ETF (CHCL.B); CI U.S. Treasury Inflation-linked Bond ETF (CTIP); CI U.S. 500 ETF (CUSA, CUSA.B); and CI U.S. 1000 ETF (CUSM.B).
ETF
Trading
Symbol
Distribution Amount
(per unit)
Payment
Frequency
CI 1-5 Year Laddered Government Strip Bond Index ETF
BXF
$0.0786
Quarterly
CI Canadian Aggregate Bond Index ETF
CAGG
$0.1290
Monthly
CI Canadian Short-Term Aggregate Bond Index ETF
CAGS
$0.1322
Monthly
CI Balanced Asset Allocation ETF
CBAL
$0.2415
Quarterly
CI Balanced+ Asset Allocation ETF Fund
CBAP
$0.0458
Quarterly
CI Galaxy Blockchain Index ETF
CBCX
$0.0000
Quarterly
CI Balanced Growth Asset Allocation ETF
CBGR
$0.2538
Quarterly
CI Balanced Income Asset Allocation ETF
CBIN
$0.3471
Quarterly
CI Digital Security Index ETF
CBUG
$0.0000
Quarterly
CI U.S. Aggregate Bond Covered Call ETF
CCBD
$0.0371
Monthly
CI Canadian Equity Index ETF
CCDN
$0.1938
Quarterly
CI Conservative Asset Allocation ETF
CCNV
$0.3028
Quarterly
CI Auspice Broad Commodity Fund (ETF Series)
CCOM
$1.0905
Quarterly
CI DoubleLine Total Return Bond US$ Fund (ETF Series)
CDLB
$0.0402
Monthly
CDLB.B
$0.0417
Monthly
CDLB.U
US$0.0417
Monthly
CI Equity+ Asset Allocation ETF Fund
CEQP
$0.0173
Quarterly
CI Equity Asset Allocation ETF
CEQT
$0.2037
Quarterly
CI MSCI World ESG Impact Index ETF
CESG
$0.2080
Quarterly
CESG.B
$0.2080
Quarterly
CI Floating Rate Income Fund (ETF Series)
CFRT
$0.0911
Monthly
CI Global Asset Allocation Private Pool (ETF Series)
CGAA
$0.0738
Monthly
CI Global Dividend Private Pool (ETF Series)
CGDI
$0.0230
Monthly
CI Global Minimum Downside Volatility Index Fund (ETF Series)
CGDV
$0.2189
Quarterly
CGDV.B
$0.2189
Quarterly
CI High Yield Bond Private Pool (ETF Series)
CGHY
$0.0228
Monthly
CGHY.U
US$0.0235
Monthly
CI Global Investment Grade ETF
CGIN
$0.0540
Monthly
CGIN.U
US$0.0540
Monthly
CI Global Quality Dividend Growth Index ETF
CGQD.B
$0.0000
Quarterly
CI Global Real Asset Private Pool (ETF Series)
CGRA
$0.0770
Monthly
CI Global Green Bond Fund (ETF Series)
CGRB
$0.0445
Monthly
CGRB.U
US$0.0461
Monthly
CI Global REIT Private Pool (ETF Series)
CGRE
$0.0860
Monthly
CI Global Sustainable Infrastructure Fund (ETF Series)
CGRN
$0.0500
Monthly
CGRN.U
US$0.0500
Monthly
CI Growth Asset Allocation ETF
CGRO
$0.2739
Quarterly
CI Global Short-Term Bond Fund (ETF Series)
CGSB
$0.0620
Monthly
CI Gold+ Giants Covered Call ETF
CGXF
$0.1417
Monthly
CGXF.U
US$0.1105
Monthly
CI Global Healthcare Leaders Index ETF
CHCL.B
$0.0000
Quarterly
CI ICBCUBS S&P China 500 Index ETF (formerly CI ICBCCS S&P China 500 Index ETF)
CHNA.B
$0.0000
Quarterly
CI Global Artificial Intelligence Fund (ETF Series)
CIAI
$0.0000
Quarterly
CI Canadian Banks Covered Call Income Class ETF
CIC
$0.0552
Monthly
CI Emerging Markets Alpha ETF
CIEM
$0.0731
Quarterly
CIEM.U
US$0.0731
Quarterly
CI Global Infrastructure Private Pool (ETF Series)
CINF
$0.0690
Monthly
CI Global Alpha Innovators ETF (formerly CI Global Alpha Innovation ETF)
CINV
$0.0000
Quarterly
CINV.U
US$0.0000
Quarterly
CI Munro Alternative Global Growth Fund (ETF Series)
CMAG
$0.0000
Quarterly
CMAG.U
US$0.0000
Quarterly
CI Marret Alternative Absolute Return Bond Fund (ETF Series)
CMAR
$0.0670
Monthly
CMAR.U
US$0.0670
Monthly
CI Alternative Diversified Opportunities Fund (ETF Series)
CMDO
$0.0640
Monthly
CMDO.U
US$0.0640
Monthly
CI Marret Alternative Enhanced Yield Fund (ETF Series)
CMEY
$0.0720
Monthly
CMEY.U
US$0.0720
Monthly
CI Money Market ETF
CMNY
$0.1002
Monthly
CI U.S. Enhanced Momentum Index ETF
CMOM
$0.0000
Quarterly
CMOM.B
$0.0000
Quarterly
CI Alternative North American Opportunities Fund (ETF Series)
CNAO
$0.0000
Quarterly
CNAO.U
US$0.0000
Quarterly
CI Alternative Investment Grade Credit Fund (ETF Series)
CRED
$0.0500
Monthly
CRED.U
US$0.0500
Monthly
CI High Interest Savings ETF
CSAV
$0.0850
Monthly
CI U.S. Treasury Inflation-Linked Bond Index ETF (CAD Hedged)
CTIP
$0.0141
Monthly
CI Target 2028 Investment Grade Bond Fund (ETF Series)
CTMA
$0.0413
Monthly
CI Target 2029 Investment Grade Bond Fund (ETF Series)
CTMB
$0.0352
Monthly
CI Target 2030 Investment Grade Bond Fund (ETF Series)
CTMC
$0.0343
Monthly
CI Global Unconstrained Bond Fund (ETF Series)
CUBD
$0.0769
Monthly
CI U.S. Minimum Downside Volatility Index ETF
CUDV
$0.0962
Quarterly
CUDV.B
$0.0962
Quarterly
CI U.S. Monthly Income Private Pool (ETF Series)
CUIG
$0.0288
Monthly
CUIG.U
US$0.0288
Monthly
CI U.S. 500 Index ETF
CUSA
$0.0000
Quarterly
CUSA.B
$0.0000
Quarterly
CI U.S. 1000 Index ETF
CUSM.B
$0.0000
Quarterly
CI Utilities Giants Covered Call ETF
CUTL
$0.0815
Monthly
CUTL.B
$0.0873
Monthly
CI U.S. Enhanced Value Index Fund (ETF Series)
CVLU
$0.1241
Quarterly
CVLU.B
$0.1241
Quarterly
CI Canadian Convertible Bond ETF
CXF
$0.0400
Monthly
CI U.S. Quality Dividend Growth Index ETF
DGR
$0.0000
Quarterly
DGR.B
$0.0000
Quarterly
DGR.U
US$0.0000
Quarterly
CI Canada Quality Dividend Growth Index ETF
DGRC
$0.0000
Quarterly
CI Europe Hedged Equity Index ETF
EHE
$0.5891
Quarterly
EHE.B
$0.5891
Quarterly
CI Emerging Markets Dividend Index ETF
EMV.B
$0.0000
Quarterly
CI Enhanced Government Bond ETF
FGO
$0.0678
Quarterly
FGO.U
US$0.0678
Quarterly
CI Health Care Giants Covered Call ETF
FHI
$0.0556
Monthly
FHI.B
$0.0655
Monthly
FHI.U
US$0.0490
Monthly
CI Investment Grade Bond ETF
FIG
$0.0320
Monthly
FIG.U
US$0.0248
Monthly
CI U.S. & Canada Lifeco Covered Call ETF
FLI
$0.0374
Monthly
CI Preferred Share ETF
FPR
$0.0768
Monthly
CI Enhanced Short Duration Bond Fund (ETF Series)
FSB
$0.0320
Monthly
FSB.U
US$0.0320
Monthly
CI Global Financial Sector ETF
FSF
$0.3026
Quarterly
CI Morningstar Canada Value Index ETF
FXM
$0.0000
Quarterly
CI International Quality Dividend Growth Index ETF
IQD
$0.0000
Quarterly
IQD.B
$0.0000
Quarterly
CI Japan Equity Index ETF
JAPN
$0.0000
Quarterly
JAPN.B
$0.0000
Quarterly
CI Energy Giants Covered Call ETF
NXF
$0.0448
Monthly
NXF.B
$0.0612
Monthly
NXF.U
US$0.0847
Monthly
CI North American Core Plus Bond ETF (formerly CI ONE North American Core Plus Bond ETF)
ONEB
$0.3451
Monthly
CI Global Core Plus Equity ETF (formerly CI ONE Global Equity ETF)
ONEQ
$0.0000
Quarterly
CI Morningstar National Bank Québec Index ETF
QXM
$0.0000
Quarterly
CI Canadian REIT ETF
RIT
$0.0675
Monthly
CI Tech Giants Covered Call ETF
TXF
$0.3779
Monthly
TXF.B
$0.4968
Monthly
TXF.U
US$0.2059
Monthly
CI U.S. MidCap Dividend Index ETF
UMI
$0.0000
Quarterly
UMI.B
$0.0000
Quarterly
CI U.S. Money Market ETF
UMNY.U
US$0.1495
Monthly
CI Morningstar International Value Index ETF
VXM
$0.0000
Quarterly
VXM.B
$0.0000
Quarterly
VXM.U
US$0.0000
Quarterly
CI Morningstar Canada Momentum Index ETF
WXM
$0.0000
Quarterly
CI Morningstar International Momentum Index ETF
ZXM
$0.6016
Quarterly
ZXM.B
$0.6016
Quarterly
Supporting Investors’ Needs
Stay in the market, minimize costs, and take advantage of a smart, simple and efficient feature designed to support investors’ needs. The CI Distribution Reinvestment Plan (DRIP) will automatically reinvest cash distributions into the CI ETF making the distribution. All of the distributions indicated in the table above will be paid in cash unless the unitholder has enrolled in the applicable DRIP of the respective ETF. For more information on how to enroll in DRIP and other considerations, please see the applicable ETF’s prospectus.
About CI Global Asset Management
CI Global Asset Management (“CI GAM”) is one of Canada’s leading investment management firms, providing a comprehensive suite of solutions – including mutual funds, exchange-traded funds and alternative investments – to help Canadians achieve their financial goals. Founded in 1965, CI GAM has built an enduring legacy of innovation, disciplined portfolio management and commitment to investor success. We partner with financial advisors, wealth management firms and institutions to serve more than 1.3 million investors. CI GAM is a subsidiary of Toronto-based CI Financial Corp., a diversified global asset and wealth management company. For more information, visit www.ci.com or follow us on LinkedIn.
Commissions, trailing commissions, management fees and expenses all may be associated with an investment in mutual funds and exchange-traded funds (ETFs). Please read the prospectus before investing. In the case of Money Market Funds, note that mutual fund securities are not covered by the Canada Deposit Insurance Corporation or by any other government deposit insurer. Important information about mutual funds and ETFs is contained in their respective prospectus. Mutual funds and ETFs are not guaranteed; their values change frequently, and past performance may not be repeated. You will usually pay brokerage fees to your dealer if you purchase or sell units of an ETF on recognized Canadian exchanges. If the units are purchased or sold on these Canadian exchanges, investors may pay more than the current net asset value when buying units of the ETF and may receive less than the current net asset value when selling them. An investor cannot invest directly in the Index. Performance of the ETF is expected to be lower than the performance of the Index.
This communication is intended for informational purposes only and does not constitute an offer to sell or the solicitation of an offer to purchase mutual funds managed by CI Global Asset Management and is not, and should not be construed as, investment, tax, legal or accounting advice, and should not be relied upon in that regard. Every effort has been made to ensure that the material contained in this document is accurate at the time of publication. Individuals should seek the advice of professionals, as appropriate, regarding any particular investment. Investors should consult their professional advisors prior to implementing any changes to their investment strategies. These investments may not be suitable to the circumstances of an investor.
CI Liquid Alternative investment funds have the ability to invest in asset classes or use investment strategies that are not permitted for conventional mutual funds. The specific strategies that differentiate these investment funds from conventional fund structure include increased use of derivatives for hedging and non-hedging purposes; increased ability to sell securities short; and the ability to borrow cash to use for investment purposes. While these strategies will be used in accordance with the investment funds' investment objectives and strategies, during certain market conditions they may accelerate the pace at which your investment decreases in value.
CI Global Asset Management is licensed by WisdomTree, Inc. to use certain WisdomTree indexes (the “WisdomTree Indexes”) and WisdomTree marks.
“WisdomTree®” and “Variably Hedged®” are registered trademarks of WisdomTree, Inc. and WisdomTree, Inc. has patent applications pending on the methodology and operation of its indexes. The ETFs referring to such indexes (the “WT Licensee Products”) are not sponsored, endorsed, sold, or promoted by WisdomTree, Inc., or its affiliates ("WisdomTree"). WisdomTree makes no representation or warranty, express or implied, and shall have no liability regarding the advisability, legality (including the accuracy or adequacy of descriptions and disclosures relating to the WT Licensee Products) or suitability of investing in or purchasing securities or other financial instruments or products generally, or of the WT Licensee Products in particular (including, without limitation, the failure of the WT Licensee Products to achieve their investment objectives) or regarding use of such indexes or any data included therein.
The S&P China 500 Index CAD (the “S&P Index”) underlying the CI ICBCUBS S&P China 500 Index ETF (the “S&P Licensed ETF”) managed by the Manager is proprietary to S&P Dow Jones Indices LLC (“S&P DJI”). S&P® and the names identifying the S&P Index are trademarks of Standard & Poor’s Financial Services LLC and have been licensed for use by S&P DJI and sublicensed for certain purposes by the Manager. The S&P Licensed ETF based on the S&P Index is not in any way sponsored, endorsed, sold or promoted by S&P DJI, its affiliates or licensors and those parties make no representations or warranties, express or implied, regarding the advisability of investing in securities generally or in the S&P Licensed ETF particularly or the ability of the S&P Index to track general market performance.
MSCI is a trademark of MSCI Inc. The MSCI indexes have been licensed for use for certain purposes by CI Global Asset Management (“CI GAM”) in connection with the CI ETFs (the “ETFs”). The ETF and the securities referred to herein are not sponsored, endorsed or promoted by MSCI Inc. or any of its affiliates (collectively, “MSCI”) and MSCI bears no liability with respect to any such fund or securities or any index on which such fund or securities are based. The ETF’s prospectus contains a more detailed description of the limited relationship MSCI has with CI GAM and any related funds.
Morningstar® is a registered trademark of Morningstar, Inc. (“Morningstar”) Morningstar® Canada Value IndexTM , Morningstar® National Bank Québec IndexTM, Morningstar® Canada Momentum IndexTM, Morningstar® International Value I IndexTM, and Morningstar® International Momentum IndexTM (the “Index”) are service marks of Morningstar and have been licensed for use for certain purposes by CI Global Asset Management (“CI GAM”). The securities of each of the CI Morningstar ETFs (the “ETFs”) are not in any way sponsored, endorsed, sold or promoted by Morningstar or any of its affiliates (collectively, ‘‘Morningstar’’), and Morningstar makes no representation or warranty, express or implied regarding the advisability of investing in securities generally or in the ETFs particularly or the ability of the Index to track general market performance.
Auspice Capital Advisors Ltd., DoubleLine Capital LP, One Capital Management, LLC, Galaxy Digital Capital Management LP, and Munro Partners are portfolio sub-advisors to certain funds offered and managed by CI Global Asset Management.
The CI Exchange-Traded Funds (ETFs) are managed by CI Global Asset Management, a wholly owned subsidiary of CI Financial Corp.
CI Global Asset Management is a registered business name of CI Investments Inc.
KFC's global modernization effort includes a new logo and packaging, menu upgrades, and restaurant redesigns, all aimed at improving the customer experience. KFC The Colonel is staying put. Almost everything else at KFC is changing.
The 74-year-old fried chicken chain is rolling out one of the biggest global brand overhauls in its history, betting that new sauces, specialty beverages, redesigned restaurants, and a refreshed logo and packaging can help it define what executives call the "next chapter of chicken."
The challenge is modernizing one of the world's most recognizable restaurant brands without losing the nostalgia and familiarity that made it iconic in the first place — and avoiding a rebranding catastrophe like Cracker Barrel experienced last year.
"We have a history of keeping pace with the consumer, and now everything we're doing is in service of making sure we're setting the standard for the modern chicken quick service restaurant," KFC Global CEO Scott Mezvinsky told Business Insider.
The effort comes as chicken has become one of the hottest segments in fast food. Raising Cane's, Dave's Hot Chicken, Chick-fil-A, and Popeyes have intensified competition, particularly in the US, where KFC is trying to regain momentum.
"KFC has become a global brand with an American problem, rather than an American brand with global ambitions," said Usha Haley, the Barton distinguished chair of international business at Wichita State University.
As of its latest earnings report, the chain continues to expand aggressively, with more than 34,000 restaurants across 151 countries, and it has posted sales growth almost everywhere over the last three quarters — except the US.
Though KFC has narrowed its customer-satisfaction gap with rivals over the past year, recent scores show the brand still faces pressure from newer chicken chains that have captured younger consumers' attention. The brand also remains behind Chick-fil-A, Popeyes, Raising Cane's, and Wingstop in US consumer spending, according to InMarket.
KFC's response to the competition has included revitalization efforts, such as the self-aware "Kentucky Fried Comeback" campaign, launched last year to reverse still-slumping sales in the US. Its new global strategy is built around menu upgrades, digital engagement, and what executives describe as a more immersive restaurant experience.
KFC's new line of sauces includes Chimichurri Ranch and Hot Honey Habanero, while its Kwench drink lineup features new shakes and boba drinks. KFC "The worst thing we can do is stand still — but the other thing that we can't do is just completely change who we are," Val Koropeckyj, KFC's global chief marketing officer said, adding that updating the strategy for a legacy brand with as much scale as KFC has is like maneuvering a cruise ship: "You can absolutely change course, but it takes intention and distance."
A cornerstone of that intention is a menu overhaul. KFC this year launched a new global beverage platform, called Kwench, and is pushing deeper into boneless chicken products with regional sauces like Chimichurri Ranch and Hot Honey Habanero, which executives say better align with what consumers crave.
"Our brand was built around buckets of chicken," Koropeckyj said. "That's not how people eat today."
Instead, she pointed to trends like snacking, grazing, flavor exploration, and beverages as growth opportunities.
KFC's beverage push in particular puts it squarely in the middle of a growing battle for younger consumers. Across the restaurant industry, chains from Starbucks to McDonald's have invested heavily in customizable, visually striking drinks as Gen Z and younger millennials increasingly treat beverages as affordable indulgences and social-media-friendly experiences.
The chicken chain's new global beverage platform includes boba refreshers, sparkling lemonades, iced coffees, and shakes designed to give customers new ways to treat themselves beyond mealtimes.
"People drink more and more often than they eat," Christophe Poirier, KFC's global chief concept officer, told Business Insider, adding that KFC executives see beverages as a way to attract younger consumers and create reasons to visit the brand beyond a traditional chicken meal. "We need to be in constant evolution to be forever young," Poirier said.
That evolution extends beyond the menu.
KFC's redesigned restaurants drew inspiration from the Sphere's screen in Las Vegas and the sleek design of the Apple Store. KFC Poirier is leading a redesign effort intended to transform KFC from a traditional quick-service restaurant into what he calls a "QXR" — a quality experience restaurant.
He cited Las Vegas' Sphere as an example of the kind of immersive environment consumers increasingly expect, and pointed to Apple Stores as inspiration for reducing friction between customers and employees.
His thinking is rooted in the belief that restaurants no longer compete only with other restaurants.
"The enemy in any place is what I'm calling the feed," Poirier said, referring to social media. "The new generation, they have no patience for boredom."
Future KFC locations will feature more dynamic digital elements, flexible spaces, and redesigned service areas intended to feel less transactional and more experiential — think immersive screens, layouts that shift with different dayparts, and hospitality-focused service areas that blur the line between employee and customer.
The goal, Poirier said, is to create restaurants that can "beat the feed."
Whether customers view the changes as innovation or catch-up remains an open question. Haley, the international business professor at Wichita State University, described the strategy as "optimization" rather than true reinvention.
"Nearly every element of KFC's strategy follows a path a faster rival already went down," Haley said. "Everything here makes KFC a better-running version of what it already is."
Michael Della Penna, chief strategy officer at InMarket, pointed to KFC's recent sales gains and growing digital engagement as signs that the chain's efforts are beginning to resonate, though there's still a long road ahead.
Still, Haley argues that KFC's greatest advantage isn't its sauces, beverages, or loyalty program, which will also be getting a facelift.
"KFC's heritage is a moat that rivals are spending fortunes to manufacture," she said. "The solution lies in modernizing the system, and sanctifying the icons."
That may be why, amid all the boba-inspired drinks, new sauces, and immersive restaurants, KFC isn't messing with the one asset its competitors can't copy: the older man in a white suit who has been the figurehead behind the brand's chicken for nearly three-quarters of a century.
As competitors continue to crowd into the chicken market, Mezvinsky is betting that KFC's history remains one of its biggest advantages.
"We know that chicken is the category growing the fastest," he said. "And we also know that we're the chicken kings."
Read next
Katherine Tangalakis-Lippert is a senior reporter on Business Insider's West Coast team. When she's not writing about trending business and tech news, from the latest supply chain snarls or advancements in AI, she covers the food and restaurant industries, specifically companies such as Starbucks and McDonald's.Some of her prior areas of focus have included coverage of the Supreme Court and emerging technologies such as quantum computing.Katherine has worked on award-nominated projects and has appeared on Good Morning America, NBC, CNN, and other outlets to discuss her reporting.Prior to joining Business Insider, she covered retail, hospitality, and nonprofits at the San Fernando Valley Business Journal and received a master's degree in investigative reporting from the University of Southern California.Reach outDo you have feedback or a story tip? Contact Katherine on Signal at byktl.50, or email her at [email protected] her on Twitter and Instagram @scrawlgirl.Some of her recent scoops, exclusives, and original stories include: Starbucks set up a new office. It's a 5-minute drive from the CEO's California home.Inside Starbucks' crackdown on cup notesEndless Shrimp was Red Lobster's rock bottom. Now it's clawing back.Chipotle's new PAC signals a change in how the company engages in politicsKFC lost its footing in the Chicken Wars. Now it's gunning for a 'Kentucky Fried Comeback.'A few other highlights include: Clarence Thomas raised him 'as a son.' Now he's facing 25-plus years on weapons and drug charges.Call her Ivanka Kushner'Maybe I'll just resign:' Federal workers react to DOGE productivity emailSpaceX launches cause late-night booms that rattle windows, set off car alarms, and may damage property. Locals are pushing back.The US-China tech race is moving from chips to the raw materials they're made of
To win over today's diners, KFC is prioritizing boneless chicken menu items, expanding its sauce options and designing its restaurants to keep customers' attention.
These days, the Yum Brands unit is facing stiff competition, both from upstart chicken chains and legacy giants like McDonald's that are betting big on the growing global popularity of chicken. While KFC claims to have invented the chicken quick-service restaurant category, being the first isn't the same as being No. 1, particularly in the U.S., where its sales have slumped in recent years.
"In an increasingly crowded category, we have a clear opportunity to set the standard for modern chicken in QSR," KFC Global CEO Scott Mezvinsky said Monday in a statement announcing the chain's "next chapter."
Tenders and drinksA focal point of the strategy is what KFC calls a "bold menu revamp."
As part of that, the chain plans to expand its boneless chicken options and improve its recipe for its existing tenders.
"We are moving from chicken-on-the bone to more and more boneless chicken," KFC Chief Concept Officer Christophe Poirier told CNBC.
"We are evolving our tenders to make sure that, nonnegotiable, we're going to have the biggest, the juiciest and the crispiest," he added.
KFC is also expanding its available sauces to appeal to consumers who like dunking, drenching or drizzling their chicken tenders. The chain's "global sauce pantry" has more than 20 varieties that often mix classic sauces with new flavors, like its chimichurri ranch. (KFC's tender- and sauce-centric spinoff restaurant chain Saucy, meanwhile, has grown to nearly a dozen locations, all in Florida.)
This month, restaurants in the United Kingdom and Ireland will begin rolling out the new tenders, as well as nine new sauces. Australia and the United States will follow later this summer, with more global markets expected throughout the rest of the year.
KFC is also launching a menu line called "Dunked," which features tenders, wings and sandwiches drenched in sauce. The menu items are already available in South Africa and India.
Like many fast-food restaurants, KFC is also expanding its range of drink options to include boba refreshers, sparkling lemonades and iced coffees under a new sub-brand called Kwench by KFC. Select Irish and British restaurants already sell Kwench drinks, but Australia and Canada will add them to their permanent menus this year.
"We can rapidly cascade a lot of initiatives that we're leading from the center," Poirier said, crediting the chain's nimble supply chain.
The chain's own restaurants will also look different as it rolls out new store designs. This summer, an "open-concept" restaurant in McKinney, Texas, will open its doors; an "immersive," two-story location in Dubai, United Arab Emirates, will follow in September.
Poirier compared the experience of visiting its upcoming "immersive" restaurant to seeing a concert at the Sphere in Las Vegas. KFC designed the store to distract diners from their phones and keep them engaged with the in-person experience.
Fresh branding is also part of the strategy. The chain's new logo features its Colonel Sanders mascot bookended on either side with "KFC," resembling the shape of its famous chicken buckets. KFC said the bucket will be "refreshed," while Sanders will receive a "subtle evolution," according to the chain.
ChallengesWith more than 34,000 locations worldwide, KFC is one of the largest global restaurant chains. It is also an important part of Yum's portfolio, particularly as its parent company seeks a sale of its struggling sister chain Pizza Hut.
But KFC has its own challenges.
In the U.S., the chain has been ceding share for years to newcomers like Raising Cane's. In 2021, KFC held 16% of the U.S. market share for chicken quick-service restaurants, putting it in second place behind Chick-fil-A, according to Barclays. By 2024, its market share had slipped to 9.4%, and Popeyes and Raising Cane's had leapfrogged KFC, dragging the chain down to the fourth spot.
Outside the U.S., KFC has been more successful. Yum considers KFC International to be one of its two "growth engines," along with top performer Taco Bell.
In its latest quarter, KFC reported same-store sales growth of 2%. Yum no longer shares the same-store sales of the chain's domestic business, implying that the segment is now considered immaterial to the company's broader results. China and Europe are KFC's two largest regions by system sales, with the U.S. in third place.
To revive its flagging U.S. business, Yum tapped Catherine Tan-Gillespie as KFC's new U.S. president more than a year ago. So far, her turnaround efforts have involved offering more value meals and bringing back Colonel Sanders.
KFC U.S. has seen same-store sales growth in its last three quarters, Tan-Gillespie told trade publication Restaurant Business earlier this month.
MAR002 demonstrates deep and durable IGF-1 suppression up to 64% with favorable PK properties potentially enabling once every two-week dosing
Phase 2/3 study of MAR002 in acromegaly to initiate in mid-2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases, today highlighted the presentation of data from its first-in-human Phase 1 study of MAR002 at the 2026 Annual Meeting of the Endocrine Society (ENDO). MAR002 is a first-in-class allosteric monoclonal antibody targeting the growth hormone receptor (GHR).
Data from the Phase 1 study support a potential best-in-disease profile of MAR002 across safety, tolerability, pharmacodynamic effect, and dosing convenience - with deep, durable IGF-1 suppression that may enable dosing as infrequently as once every two weeks, compared to the daily subcutaneous injections required by the current standard of care.
“The Phase 1 data presented at ENDO provide compelling proof-of-mechanism for MAR002 and strengthen our confidence as we advance into a Phase 2/3 study in patients with acromegaly expected to begin in the coming weeks,” said Rebecca Juliano, Ph.D., chief development officer of Marea Therapeutics. “MAR002 demonstrated deep and durable suppression of IGF-1, a validated biomarker and regulatory endpoint in acromegaly, while exhibiting pharmacokinetic properties that may support convenient dosing as infrequently as every two weeks. By directly blocking growth hormone signaling at the receptor level, MAR002 has the potential to deliver meaningful biochemical control for a broad population of patients and establish a new standard of care in acromegaly.”
“Acromegaly remains a disorder of significant unmet need, with fewer than 35% of patients achieving optimal disease control on first-line medical therapy,” said Shlomo Melmed M.D., Distinguished Professor and Dean at Cedars-Sinai. “The depth of initial IGF-1 suppression reported with MAR002 of up to 64% is particularly notable, as it appears to exceed levels seen with previously reported therapies in acromegaly. Based on these early findings, and if proven safe, MAR002 has the potential to become a significant advancement in both efficacy and treatment convenience for patients with acromegaly.”
Presentation Highlights
The first-in-human, randomized, blinded, parallel-group, placebo-controlled Phase 1 study enrolled healthy adult male volunteers and single ascending doses of MAR002 demonstrated a favorable safety and tolerability profile, with no serious adverse events or dose-limiting toxicities. Treatment with MAR002 resulted in robust and durable dose-dependent reductions in circulating insulin-like growth factor-1 (IGF-1) with up to 64% peak suppression. Favorable pharmacokinetic (PK) profile support bi-weekly to monthly dosing. About Acromegaly
Acromegaly is a rare, chronic, progressive endocrine disorder caused by prolonged exposure to excess growth hormone (GH), most commonly due to a GH-secreting pituitary adenoma, resulting in elevated insulin-like growth factor-1 (IGF-1). It leads to the abnormal enlargement of the hands, feet, and facial features, and if left untreated, can result in severe systemic complications. GH receptor antagonists (GHRA) offer therapeutic advantages in acromegaly by directly blocking GH signaling, lowering IGF-1, and improving insulin sensitivity. However, the only approved GHRA, pegvisomant, requires daily administration, resulting in suboptimal patient adherence and reduced real-world efficacy.
About MAR002
MAR002 is a potent and selective half-life-extended, allosteric, human monoclonal growth hormone receptor antagonist (GHRA) antibody being developed for the treatment of acromegaly. The in vivo PK and PD properties of MAR002 are predictable and typical of a half-life extended human antibody, showing a long duration of action compatible with infrequent subcutaneous dose administration in humans. These characteristics support its potential to offer an effective and convenient treatment for patients with acromegaly.
About Marea Therapeutics
Marea Therapeutics is a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases. The company’s lead therapy, MAR001, is in Phase 2b clinical development for the treatment of severe hypertriglyceridemia (sHTG), a condition characterized by very high triglyceride levels. The company is also advancing MAR002 for the treatment of acromegaly. To learn more, please visit www.mareatx.com and follow us on LinkedIn and X.
Toyota’s (NYSE:TM | TM Price Prediction) American depositary receipts have taken a beating in 2026, sliding 18.27% year to date as U.S. tariffs gut North American profitability and global volumes soften. Yet the setup remains compelling.
The stock trades at $174.95, and the 24/7 Wall St. price target points to $240.94 over the next 12 months. That signals meaningful upside for the world’s largest automaker, and the model rates shares a buy with high conviction.
24/7 Wall St. Price Target Summary Metric Value Current Price $174.95 24/7 Wall St. Price Target $240.94 Upside 37.72% Recommendation BUY Confidence Level 90% A Tariff-Driven Reset Has Created an Entry Point Toyota shares peaked at $245.51 in February 2026 and have unwound to current levels, leaving the stock down 6.39% over the past month and 2.43% over the past year.
The pullback stems from a brutal FY2026 result reported on May 8, 2026: full-year revenue of $323.62B, operating income down 21.5% to $24.05B, and a $8.81B direct hit from U.S. tariffs. North America swung to a $1.23B operating loss.
Global vehicle sales fell 3.1% year over year in April, Middle East exports collapsed 91.7%, and SoftBank surpassed Toyota as Japan’s largest company by market cap for the first time in 20 years. Weekly RSI sits at 33.35, an oversold reading that historically marks reversal zones.
The Case for $262 and Higher The bull-case scenario lands at $262.41, a 49.99% return. Electrified vehicles account for 48.1% of retail sales, BEV volume jumped 68.4% to 243K units in FY26, and Toyota guides FY27 BEV sales to 598K units, up 146.1%.
The Arene software platform, AREA35 production initiative, and a value-chain push targeting JPY 2.1T by 2030 build a credible 20% ROE roadmap.
Analyst targets back this optimism. Freedom Capital upgraded Toyota to Buy with a $230 target, citing hybrid demand approaching 5M units. The consensus 12-month target of $256.52 reflects 2 Strong Buy, 1 Buy, and 1 Hold rating. A $23.35B Toyota Industries take-private settled in May 2026 tightens governance and removes a long-standing cross-holding overhang.
The Risks Worth Watching The bear scenario pencils to $212.42, a positive return but well shy of the base case. FY27 guidance calls for operating income to fall 20.3% to roughly $19.16B, including a 400B yen incremental tariff and Middle East drag. BYD’s chairman has publicly targeted overtaking Toyota within five years, and China profitability remains under pressure.
Bulls argue the FY27 guide bakes in conservative 150 yen/USD FX and front-loads tariff risk. Operating cash flow of $34.94B and an $80.83B cash pile leave room to absorb the cycle. At a 10 P/E and 0.92 price-to-book, the downside is already priced in.
Toyota Price Prediction 2026-2030 The 24/7 Wall St. price target of $240.94 represents 37.72% upside, and I’m leaning into the buy rating with 90% confidence. The tipping factor is valuation: an oversold mega-cap trading near 9x earnings with positive free cash flow, a 3.58% dividend yield, and a credible electrification ramp.
The setup looks favorable on a 12 to 18 month horizon. I’d stay on the sidelines if you expect U.S. tariffs to escalate further or if FY27 guidance gets cut at the half-year mark.
Looking ahead, here is where our model projects Toyota could trade, assuming current growth trajectories and tariff conditions normalize.
Year 24/7 Wall St. Price Target 2026 $240.94 2027 $300.92 2028 $351.27 2029 $394.12 2030 $429.30 These projections assume Toyota executes on its hybrid and BEV roadmap and that U.S. tariff pressure eases by FY28. Material upside or downside could come from a BYD-driven share shift, a sharper yen reversal, or breakthrough adoption of the Arene software stack.
A Cinematic Sponsored Documentary Marking Nearly 70 Years of Toyota in America To Air on Discovery Turbo and Discovery Go
, /PRNewswire/ -- Seven decades. In the life of a nation, it's a chapter. In the life of an industry, it's an evolution. But for one company, it has been a promise kept – a promise not just to sell cars in America, but to assemble them here, alongside the people who drive them.
Built to Last: Toyota’s Mobility Journey | A Cinematic Sponsored Documentary Marking Nearly 70 Years of Toyota in America To Air on Discovery Turbo and Discovery Go As America approaches its 250th birthday, the question isn't just how far we've come. It's where we're headed next. Who assembles the vehicles that keep America moving? And how is one of the world's largest automakers preparing for an electrified future while remaining deeply rooted in the communities it has called home for nearly 70 years?
Those questions are at the heart of Built to Last: Toyota's Mobility Journey — a cinematic half-hour documentary produced by Bader Media and funded by Toyota Motor North America. Hosted by Dallas-Fort Worth-based broadcaster Celena Rae, the program takes viewers behind the scenes of Toyota's decades in America — from the first Toyopet sedan in 1950's to the rolling hills of Georgetown, Kentucky, to the new battery frontiers of Liberty, North Carolina.
The story spans eleven U.S. manufacturing plants, 1,500 dealers, and nearly 50,000 American team members. It traces Toyota's nearly 70-year commitment — from assembly lines and supplier networks to cutting-edge battery production. That commitment continues today through more than $60 billion in announced U.S. investments, including the landmark $14 billion battery manufacturing facility in Liberty, North Carolina — the largest economic development project in the state's history.
Along the way, Celena Rae meets with Toyota leaders, U.S. governors and senators, and the men and women on the factory floor who bring the company's vision to life. Together, they reveal how Toyota is navigating one of the biggest transformations in automotive history through a multi-pathway approach — advancing hybrid, plug-in hybrid, battery electric, and emerging technologies to deliver practical solutions for drivers, communities, and the future of mobility.
DISTRIBUTION
Built to Last: Toyota's Mobility Journey premieres Saturday, June 27, 2026 at 7 AM (ET & PT) on Discovery Turbo, with an encore airing on July 11, 2026 and on-demand viewing on Discovery Go. The 30-minute television program also includes a 30-second branded "Did You Know?" spot marking the 40th anniversary of Toyota Motor Manufacturing Kentucky.
Premiere schedule:
National Premiere: Saturday, June 27, 2026, 7 AM (ET & PT) on Discovery Turbo with an encore airing on Saturday, July 11, 2026. Discovery Go (Streaming): https://go.discovery.com/ WHAT VIEWERS WILL LEARN
Roots & Commitment: Inside Toyota's flagship Kentucky operation in Georgetown — Toyota's largest manufacturing plant in the world, spanning nine million square feet — where 87 "Day One" team members from 1986 are still on the floor today, anchoring a new $800 million investment in electrification. Powering the Future: A first look at the $14 billion battery "mega-site" in Liberty, North Carolina — the largest economic development project in that state's history — designed to produce 30 gigawatt-hours of battery power annually for hybrid, plug-in hybrid and battery electric vehicles assembled in the United States. Toyota Across America: A coast-to-coast exploration of Toyota's American story—from Toyota's headquarters in Plano, Texas, to the engine lines of Huntsville, Alabama; the truck capital of San Antonio; Buffalo, West Virginia's hybrid transformation; and the families, workers, and communities that have shaped generations of manufacturing excellence in Princeton, Indiana. Safety, Sustainability & Spirit: A look at the "living blueprint" for sustainability at Toyota's Plano headquarters — including one of the largest corporate solar arrays in Texas and rainwater cisterns that collect as much as 400,000 gallons — and inside Toyota's Collaborative Safety Research Center in Ann Arbor, Michigan, where life-saving innovations are shared as a "gift to the industry." A Multi-Pathway Strategy: A clear-eyed look at Toyota's many electrified vehicle options across the Toyota and Lexus brands, and how a portfolio approach including hybrids, plug-in hybrids and battery electrics are meeting the needs of every type of American driver. Join us as the program follows Celena Rae's journey across the heartland — from the Lone Star State, to the rolling hills of Kentucky, to the new battery frontiers of North Carolina — through the people, the innovation, and the spirit that are truly built to last.
About Toyota
Toyota (NYSE:TM) has been a part of the cultural fabric in the U.S. for nearly 70 years, and is committed to advancing sustainable, next-generation mobility through our Toyota and Lexus brands, plus our nearly 1,500 dealerships.
Toyota directly employs approximately 48,000 people in the U.S. who have contributed to the design, engineering, and assembly of more than 36 million cars and trucks at our 11 manufacturing plants. In 2025, Toyota's plant in North Carolina began to assemble automotive batteries for electrified vehicles.
To help inspire the next generation for careers in advanced manufacturing, Toyota launched its in-person tour booking platform and virtual tour experience at www.TourToyota.com allowing guests to schedule a live tour to see several of our U.S. manufacturing facilities in action or visit all plants virtually from anywhere around the globe.
For more information about Toyota, visit www.ToyotaNewsroom.com.
MEDIA CONTACTS
Toyota Motor North America
Ed Hellwig
[email protected]
Bader Media
Hena Cuevas
+1.202.503.4460
[email protected]
Nano Dimension Conducted a Rigorous Multi-Month Strategic Review, Assessing Approximately 20 Companies Before Selecting Infinite Epigenetics as the Most Compelling Path to Long-Term Value CreationProposed Combination Would Deploy Nano Dimension’s Capital Base and Nasdaq listing into a High-Growth Healthcare AI OpportunityExisting Nano Shareholders Expected to Retain Meaningful Minority Ownership in Combined Company on a Stated Value for Nano Dimension’s Shares that Reflects a 20% Premium to Nano Dimension’s Estimated Net Cash at ClosingInfinite Epigenetics Transaction Value of $890 million Infinite Epigenetics Targets a $90B+ U.S. Clinical Diagnostics Market Opportunity Across its Core Disease States, Combining One of the Largest Private Epigenetic Datasets with a Proprietary Biological AI Platform to Provide Earlier Warning of Disease RiskPlatform Includes Revenue-Generating Diagnostics Operations with 120,000+ Epigenetic Samples Collected Since 2020Nano and Infinite Epigenetics to Host Conference Call Today at 8:30 AM ET WALTHAM, Mass., June 15, 2026 (GLOBE NEWSWIRE) -- Nano Dimension Ltd. (Nasdaq: NNDM) (“Nano Dimension,” “Nano”) today announced it has entered into a non-binding term sheet for a proposed business combination (“combination”) with Infinite Epigenetics™ (“Infinite Epigenetics,” “Infinite”), an artificial intelligence (“AI”)-powered preventive health and diagnostics company building a proprietary biological AI platform to read, interpret, and apply epigenetic signals at scale.
Epigenetics is the science of gene expression, shaped by lifestyle, aging, stress, and environmental factors. While traditional genetics dictates the exact sequence of one's DNA, epigenetics serves as a set of switches that can turn genes "on" or "off" without altering the underlying code. Epigenetic gene expression represents approximately 80% of one’s health, while their underlying DNA code accounts for the remaining approximately 20%. Infinite Epigenetics’ proprietary biological AI foundation model is trained on the epigenome, the operating system of the body, and reads more than 1 million epigenetic signals from a single test. Every test processed by the platform delivers actionable insights for both clinicians and patients. Furthermore, these tests strengthen the model, improving its ability to detect and predict disease earlier.
Infinite Epigenetics was co-founded by Dr. Matthew Dawson, Dr. Michael Mallin, and Brad Keywell, an entrepreneur and Original Investor and Board Member of Tempus AI, Inc. Infinite Epigenetics is building a proprietary biological AI platform that leverages the technology, proprietary data and commercial operations of its subsidiaries, TruDiagnostic, its CLIA-certified laboratory founded in 2019, and Tally Health, a consumer longevity and preventative health company founded in 2021. While the Infinite Epigenetics name and platform are relatively new, they are anchored in established operating businesses with meaningful commercial traction.
David Stehlin, Chief Executive Officer of Nano Dimension, said: “Infinite Epigenetics represented the most attractive opportunity for us to enhance shareholder value. Together with our financial advisor, Houlihan Lokey, we conducted a thorough review of approximately 20 potential opportunities across multiple sectors over many months. The company checked the key boxes we were looking for: a proven technology platform with: revenue-generating operations; a large, growing addressable market; world-class customers and partners; and a strong leadership team, experienced board members, and highly accomplished investors. We believe Infinite Epigenetics has the potential to become a category-defining company at the intersection of healthcare, biological data and AI, and that the proposed business combination would create a clear and compelling path for long-term shareholder value creation.”
As we approach the culmination of Phase 3 of Nano Dimension’s strategic plan to maximize long-term shareholder value, the proposed combination would deploy Nano’s capital base, Nasdaq platform and strategic flexibility into a high-growth healthcare AI opportunity. The transaction is intended to provide Nano shareholders with exposure to a significantly larger addressable market, while providing Infinite Epigenetics with the publicly traded company platform and resources to accelerate its mission.
Robert Pons, Chairman of Nano Dimension, said: “The proposed business combination with Infinite Epigenetics represents the next major step in Nano’s strategic plan. We believe Infinite Epigenetics offers a compelling opportunity with meaningful long-term potential, and one that we are confident can deliver lasting value for our shareholders.”
Infinite is initially focused on four major chronic diseases: cardiovascular disease, Type 2 diabetes, chronic obstructive pulmonary disease (“COPD”) and metabolic dysfunction-associated steatotic liver disease (“MASLD,” formerly known as fatty liver disease). These diseases impact more than 4 billion people worldwide and chronic diseases account for more than $4 trillion in annual healthcare costs that could be reduced through earlier and more accurate diagnosis. Infinite pairs one of the largest private collections of epigenetic data with its biological AI foundation model to address these conditions at scale.
Through TruDiagnostic and Tally Health, Infinite Epigenetics has built revenue-generating commercial diagnostics operations, collected more than 120,000 epigenetic samples since 2020, and developed a proprietary DNA methylation dataset. Since TruDiagnostic’s founding, the business has generated growing revenue while expanding its testing capabilities, research relationships, and commercial applications. Infinite has also built extensive biological and technical intellectual property (“IP”) and maintains research collaborations with leading institutions, including Harvard, Yale, Duke, Stanford, and others.
Brad Keywell, Co-Founder of Infinite Epigenetics and Original Investor and Board Member of Tempus AI, said: “We believe the most valuable healthcare AI platforms will be built on proprietary biological data, leveraging AI for novel discoveries and insights. Infinite Epigenetics has the opportunity to bring that platform logic to epigenetics, one of the most powerful and dynamic data layers in medicine.”
Transaction Overview
Under the term sheet, the proposed transaction contemplates that Nano Dimension, or a successor publicly traded company, would acquire 100% of the equity interests of Infinite Epigenetics through a merger, consolidation or other transaction structure to be mutually agreed by the parties. Upon closing of the proposed transaction, if any, the combined company is expected to operate under the Infinite Epigenetics name and continue trading on the Nasdaq Capital Market under the proposed ticker symbol “IEAI.”
Existing Nano Dimension shareholders are expected to retain a meaningful minority ownership interest in the combined company based on a stated value for Nano shares that reflects a 20% premium to Nano Dimension’s estimated net cash at closing, subject to final negotiation and execution of a definitive agreement. The parties expect that the combined company will have over $400 million in cash at closing, which the parties believe will provide ample runway and financial flexibility as Infinite Epigenetics advances toward positive cash flow, without the need for additional capital raises.
Nano believes this structure provides existing shareholders with value recognition for its cash position and listing and enables them to participate in the potential upside of a high-growth healthcare AI opportunity.
Additionally, the pre-combination Nano Dimension shareholders would receive a contingent value right (“CVR”) entitling them to certain net proceeds, if any, received by a newly formed entity and liquidation trust from the disposition of certain Nano legacy assets following the closing of the combination.
The term sheet provides for a 30-day period of mutual exclusivity, during which Nano Dimension will conduct confirmatory due diligence on Infinite Epigenetics, and the parties will finalize the terms of a definitive merger agreement.
Dr. Matthew Dawson, Co-Founder and Chief Executive Officer of Infinite Epigenetics, is expected to serve as Chief Executive Officer of the combined company. The board is expected to include representatives designated by Nano, as well as key Infinite Epigenetics leaders and directors, including Brad Keywell, an entrepreneur and Original Investor and Board Member of Tempus AI; U.S. Navy Vice Admiral (Ret.) Raquel C. “Rocky” Bono, M.D., member of the Board of Directors of Humana and former Chief Executive Officer and Director of the Defense Health Agency; Dr. Matthew Dawson; Dr. Michael Mallin; and other directors to be mutually agreed upon by the parties.
Nano Dimension expects to announce additional details regarding the proposed business combination if and when a definitive agreement is executed.
No assurance can be made that the parties will successfully negotiate and enter into a definitive agreement, or that the proposed transaction will be consummated on the terms or timeframe currently contemplated, or at all. Any transaction would be subject to the completion of satisfactory due diligence, the negotiation of a definitive agreement and related ancillary agreements, satisfaction of conditions negotiated therein, Board of Directors and shareholder approvals, regulatory approvals, and other customary conditions.
Strategic Rationale
Exact Sciences helped demonstrate that molecular diagnostics can scale in the public markets. GRAIL helped validate the potential of methylation-based testing from blood. Tempus AI helped demonstrate the power of proprietary clinical data and AI to create a new category in precision medicine. Nano believes Infinite Epigenetics represents a potential “Digital Health 3.0” platform: moving beyond traditional disease detection toward AI-enabled interpretation of biological signals that can support earlier, more proactive health insights.
Nano believes the combination creates a differentiated AI-powered diagnostics and preventive health platform with a durable, self-reinforcing competitive moat. Each test processed adds to Infinite's proprietary biological dataset, compounding its value across clinical diagnostics, consumer longevity, pharma data, and enterprise health applications over time.
Dr. Matthew Dawson, Co-Founder and Chief Executive Officer of Infinite Epigenetics, said: “Our mission is to help move healthcare from reactive to proactive by giving clinicians and individuals earlier insight into what the body is signaling, often before symptoms appear. Detecting risk sooner is how we change outcomes for the chronic diseases that affect billions of people, and epigenetics gives us a dynamic, real-time view of that biology. The proposed combination with Nano Dimension would provide the capital and strategic flexibility to bring these insights to people at scale.”
Infinite Epigenetics Leadership
Infinite Epigenetics is led by a team of healthcare, technology, and AI entrepreneurs, scientists, and operators with experience building, scaling, and exiting category-defining companies. The founding team and leadership have collectively founded more than 10 companies, participated in prior ventures representing more than $20 billion of aggregate exit value, and contributed to more than 50 peer-reviewed studies.
Investor Presentation
An investor presentation containing additional information regarding this transaction is available here.
Conference Call and Webcast
Nano Dimension and Infinite Epigenetics will host a conference call and webcast today, June 15, 2026, at 8:30 a.m. ET to discuss the proposed business combination, strategic rationale, and Infinite Epigenetics’ AI-powered preventive health and diagnostics platform.
Participants can pre-register for the conference call in order to receive dial in information via this link: https://dpregister.com/sreg/10209845/10437fe0ae2
Participants can also dial-in/connect by following the below:
Listen in via U.S. dial-in: 1-844-695-5517
Listen via international dial-in: 1-412-902-6751
Listen via Israel toll free: 1-80-9212373
Listen via webcast: https://event.choruscall.com/mediaframe/webcast.html?webcastid=x3sIKph8
For those unable to participate in the conference call, a replay of the webcast and investor presentation will be available on Nano Dimension’s investor relations website following the conclusion of the call.
Advisors
Paul Hastings LLP is serving as legal counsel to Nano Dimension and Houlihan Lokey is serving as Nano Dimension's financial advisor. Latham & Watkins LLP is serving as legal counsel to Infinite Epigenetics and Wells Fargo Securities is serving as financial advisor and capital markets advisor to Infinite Epigenetics.
About Nano Dimension Ltd.
Nano Dimension Ltd. (Nasdaq: NNDM) has historically delivered advanced digital manufacturing technologies serving customers across the defense, aerospace, automotive, electronics and medical device industry segments. Following a strategic review process initiated in 2025, the Company has focused on streamlining its operations, reducing cash burn, monetizing product lines and evaluating opportunities to deploy its capital base and publicly traded company platform into a more compelling long-term value creation opportunity. Nano Dimension continues to operate its remaining product lines, while the Company advances its strategic plan and evaluates the proposed business combination with Infinite Epigenetics. For more information, please visit www.nano-di.com.
About Infinite Epigenetics
Infinite Epigenetics is an AI-powered, preventive health and diagnostics company building a proprietary biological AI platform to read, interpret, and apply epigenetic signals at scale. Powered by one of the world’s largest private DNA methylation datasets and supported by a deep body of peer-reviewed research, the company partners with biotech innovators, researchers, and healthcare organizations to translate epigenetic insights into actionable diagnostic and clinical applications. Its operating portfolio includes TruDiagnostic™, a CLIA-certified laboratory and clinical epigenetic testing company, and Tally Health™, a consumer longevity and preventive health company. For more information, visit www.infiniteepigenetics.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding Nano Dimension’s strategic plan, strategic alternatives review process, expectations on the timing, economics and success of the proposed business combination, beliefs regarding the future success and long-term growth opportunities of Infinite Epigenetics and the combined company, expectations for the structure of the proposed business combination, belief that deploying Nano’s capital and publicly traded company platform into a high growth healthcare and data business offers a more compelling path to long-term value creation than continuing to scale within the advanced digital manufacturing sector, and all other statements other than statements of historical fact that address activities, events or developments that Nano Dimension intends, expects, projects, believes or anticipates will or may occur in the future. Forward-looking statements may be characterized by terminology such as “believe,” “project,” “expect,” “anticipate,” “estimate,” “forecast,” “outlook,” “target,” “endeavor,” “seek,” “predict,” “intend,” “strategy,” “plan,” “may,” “could,” “should,” “will,” “would,” “continue,” “likely,” or the negative thereof or variations thereon or similar terminology generally intended to identify forward-looking statements. Such statements are based on management’s beliefs and assumptions made based on information currently available to management. These forward-looking statements involve known and unknown risks and uncertainties, which may cause the Company’s actual results and performance to be materially different from those expressed or implied in the forward-looking statements. Accordingly, the Company cautions shareholders that any such forward-looking statements are not guarantees of future performance and are subject to risks, assumptions, estimates and uncertainties that are difficult to predict. The forward-looking statements contained or implied in this communication are subject to other risks and uncertainties, including, but not limited to (i) the risk that Nano Dimension and Infinite Epigenetics are unable to negotiate and enter into a definitive agreement for the proposed combination; (ii) the risk that the conditions to the closing (including any necessary shareholder approvals) are not satisfied; (iii) uncertainties as to the timing of the consummation of the proposed combination and the ability of each of Nano Dimension and Infinite Epigenetics to consummate the proposed combination; (iv) effect of the announcement of the proposed combination on the ability of Nano Dimension and Infinite Epigenetics to continue to operate their respective businesses and retain and hire key personnel and to maintain favorable business relationships; (v) risks related to the failure or delay in obtaining required approvals from any governmental or regulatory entity necessary to consummate the proposed combination; (vi) changes in the exchange ratio that could cause Nano Dimension’s shareholders and Infinite Epigenetics’ stockholders to own more or less of the combined company than is currently anticipated; (vii) risks related to the market price of Nano Dimension’s shares relative to the value suggested by the term sheet; (viii) unexpected costs, charges or expenses resulting from the proposed combination; (ix) the potential for the occurrence of any event, change or other circumstance or condition that could give rise to the termination of the definitive agreement for the proposed combination and the other agreements entered into in connection therewith; (x) the possibility that holders of CVRs may never receive any proceeds therefrom; (xi) changes in demand for Nano Dimenson’s or Infinite Epigenetics’ products and services; (xii) global market, political and economic conditions, and conditions in the countries in which Nano Dimension and Infinite Epigenetics operate; (xiii) the impact of changes in law and government regulations; (xiv) competition in the epigenetics health industry; (xv) the risk of litigation, including any proceedings that may be instituted against Nano Dimension or Infinite Epigenetics related to the proposed combination; (xvi) the impact of rapid technological change in the epigenetics health industry; and (xvii) those discussed under the heading “Risk Factors” in Nano Dimension’s annual report on Form 10-K for the fiscal year ended December 31, 2025, filed with the U.S. Securities and Exchange Commission (the “SEC”) on March 31, 2026, and in any subsequent filings with the SEC.
Except as otherwise required by law, Nano Dimension undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this communication.
Additional Information and Where to Find It
The Company has filed a preliminary proxy statement and intends to file a proxy statement and WHITE proxy card with the SEC in connection with its solicitation of proxies for an extraordinary general meeting of shareholders that will include, among other proposals, a proposal to approve on a non-binding advisory basis a resolution regarding the continuation of Nano Dimension’s strategic alternatives review process including any related transaction approved by the Board (the “Extraordinary General Meeting”). THE COMPANY’S SHAREHOLDERS ARE STRONGLY ENCOURAGED TO READ THE DEFINITIVE PROXY STATEMENT, ANY AMENDMENTS OR SUPPLEMENTS THERETO, AND THE ACCOMPANYING WHITE PROXY CARD WHEN THEY BECOME AVAILABLE, AS THEY WILL CONTAIN IMPORTANT INFORMATION.
Shareholders may obtain the proxy statement, any amendments or supplements to the proxy statement and other documents as and when filed by the Company with the SEC without charge from the SEC’s website at www.sec.gov.
This communication also relates to a proposed combination involving Nano Dimension and Infinite Epigenetics and may be deemed to be solicitation material in respect of the proposed combination. In connection with the proposed combination, Nano Dimension intends to file with the Securities and Exchange Commission (the “SEC”) a registration statement on Form S-4 that will contain a proxy statement of Nano Dimension that will constitute a prospectus with respect to shares of Nano Dimension’s stock to be issued in the proposed combination (the “Proxy Statement/Prospectus”). Nano Dimension may also file other documents with the SEC regarding the proposed combination. This document is not a substitute for the Proxy Statement/Prospectus or any other document which Nano Dimension may file with the SEC. INVESTORS AND SECURITYHOLDERS OF NANO DIMENSION AND INFINTE EPIGENETICS ARE URGED TO READ THE PROXY STATEMENT/PROSPECTUS AND ANY OTHER RELEVANT DOCUMENTS THAT WILL BE FILED BY NANO DIMENSION WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED COMBINATION AND RELATED MATTERS. Nano Dimension shareholders and Infinite Epigenetics stockholders will also be able to obtain free copies of the Proxy Statement/Prospectus (when available) and other documents containing important information about Nano Dimension, Infinite Epigenetics and the proposed combination that will be filed with the SEC by Nano Dimension through the website maintained by the SEC at www.sec.gov. Copies of the documents filed with the SEC by Nano Dimension will also be available free of charge on Nano Dimension’s website at https://investors.nano-di.com/sec-filings-1/default.aspx or by contacting Nano Dimension’s investor relations department by email at [email protected].
Participants in the Solicitation
The Company, the President, Chief Executive Officer and Director, David Stehlin, and each of its non-employee directors (namely, Robert Pons; Phillip Borenstein; Dr. Joshua Rosensweig and Andrew Sriubas) are deemed to be “participants” (as defined in Section 14(a) of the Securities Exchange Act of 1934) in the solicitation of proxies from the Company’s shareholders in connection with the matters to be considered at the Extraordinary General Meeting. Information about the compensation of our non-employee Directors is set forth in the sections titled “Director Compensation” and “Director Compensation Table” in the Company’s Annual Report, at pages 54-56, and is available here. Information about the compensation of our President, Chief Executive Officer, and Director, David Stehlin, is set forth in the section titled “Executive Compensation” in the Annual Report, at pages 56-64, and is available here. Information regarding the participants’ holdings of the Company’s securities can be found in the section titled “Security Ownership of Certain Beneficial Owners and Management and Related Shareholder Matters” in the Company’s Annual Report on pages 64-65 and is available here, and as updated in the filings referenced below. Supplemental information regarding the participants’ holdings of the Company’s securities can be found in SEC filings on Statements of Change in Ownership on Form 4 filed with the SEC on May 29, 2026 for Mr. Stehlin (available here) and June 12, 2026 (available here). Such filings are available on the Company’s website at https://investors.nano-di.com/sec-filings-1/default.aspx or through the SEC’s website via the links referenced above.
Updated information regarding the participants’ direct or indirect interests, by security holdings or otherwise, is be set forth in the Company’s preliminary proxy statement on Schedule 14A and will be set forth in the Company’s definitive proxy statement and other materials to be filed with the SEC in connection with the Extraordinary General Meeting.
Nano Dimension and its directors and executive officers may be deemed to be “participants” (as defined in Section 14(a) of the Securities Exchange Act of 1934) in the solicitation of proxies from Nano Dimension’s shareholders in connection with the proposed combination. Information regarding the persons who may, under SEC rules, be deemed participants in the solicitation of proxies from Nano Dimension’s shareholders in connection with the proposed combination will be set forth in the Proxy Statement/Prospectus on Form S-4 for the proposed combination, which is expected to be filed with the SEC by Nano Dimension. Investors and securityholders of Nano Dimension and Infinite Epigenetics are urged to read the Proxy Statement/Prospectus and other relevant documents that will be filed with the SEC by Nano Dimension carefully and in their entirety when they become available because they will contain important information about the proposed combination.
The Underwriting BusinessThe World Cup OpportunityRobinhood Shares SurgeHOOD Price Action: At the time of publication, Robinhood shares are trading 4.92% higher at $97.77, according to data from Benzinga Pro.
Image via Shutterstock
This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Market News and Data brought to you by Benzinga APIs
FREMONT, Calif., June 15, 2026 (GLOBE NEWSWIRE) -- Enphase Energy, Inc. (NASDAQ: ENPH), a global energy technology company and the world's leading supplier of microinverter-based solar and battery systems, today announced the appointment of Shanker Trivedi to its board of directors, effective immediately.
Mr. Trivedi recently retired from NVIDIA Corporation after a distinguished 17-year tenure, where he last served as senior vice president of enterprise business. During his time there, he played a key role in leading the growth of NVIDIA's data center and enterprise businesses, helping drive the company's expansion into a global leader in accelerated computing and artificial intelligence infrastructure.
"We are delighted to welcome Shanker to our board of directors," said Badri Kothandaraman, president and CEO of Enphase Energy. "Shanker brings decades of experience building global technology businesses and has driven advances in one of the most significant technology transformations of our time — the rise of AI and accelerated computing. His deep expertise in data centers, enterprise infrastructure, go-to-market strategy, and ecosystem development will be invaluable as Enphase expands its technology platform and explores new opportunities in energy management, power conversion, and AI-driven energy infrastructure."
"I am honored to join Enphase’s board of directors," said Mr. Trivedi. "Enphase has established itself as a global leader in energy technology through a relentless focus on innovation, product quality, and customer experience. As electrification, AI, and energy infrastructure increasingly converge, I believe Enphase is uniquely positioned to deliver differentiated solutions designed to help customers manage and optimize energy. I look forward to working with the board and management team as the company pursues its next phase of growth."
Mr. Trivedi brings more than 30 years of leadership experience in enterprise technology, data centers, cloud infrastructure, and go-to-market execution. At NVIDIA, Mr. Trivedi led worldwide sales for data center and professional visualization products, as well as business development for all industry verticals other than gaming, including manufacturing, healthcare, financial services, telecommunications, government, and education. Prior to NVIDIA, he held various senior leadership positions at Callidus Software, Sun Microsystems, IBM, and ICL. Mr. Trivedi earned a Master of Business Administration degree from the Indian Institute of Management Calcutta and a Master of Science degree in Mathematics and Computer Science from the Indian Institute of Technology Delhi.
About Enphase Energy, Inc.
Enphase Energy, a global energy technology company based in Fremont, CA, is the world's leading supplier of microinverter-based solar and battery systems, EV chargers, home energy management systems, and virtual power plant (VPP) solutions. Enphase products enable people to harness the sun to make, use, save, and sell their own power, all controlled through the Enphase App. The company revolutionized the solar industry with its microinverter-based technology and has shipped approximately 87.8 million microinverters, with more than 5.2 million Enphase-based systems deployed in over 165 countries. For more information, visit https://enphase.com/.
Forward-Looking Statements
This press release may contain forward-looking statements, including statements regarding the expected benefits of Mr. Trivedi's appointment to the board of directors, Enphase Energy's growth opportunities, technology roadmap, market expansion initiatives, and future business prospects. These forward-looking statements are based on Enphase Energy’s current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those contemplated by these forward-looking statements as a result of such risks and uncertainties. Such risks include, but are not limited to, product development, market demand and competitive environments, and other factors discussed in Enphase Energy's filings with the Securities and Exchange Commission, including those risks described in more detail in Enphase Energy's most recently filed Annual Report on Form 10-K, Quarterly Report on Form 10-Q, and other filings made from time to time with the Securities and Exchange Commission. Enphase Energy undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events, or changes in its expectations, except as required by law.
Insight Holdings Group, LLC, one of several affiliated entities within the Insight Partners family of funds -- which collectively carry a 10% owner designation for Coursera (COUR +0.19%) -- reported the indirect sale of 78,628 shares of common stock for a transaction value of approximately $447,000 on May 18, 2026, according to an SEC Form 4 filing.
Transaction summaryMetricValueShares sold78,628Shares sold (indirect)78,628Transaction value$447,000Post-transaction shares (direct)0Post-transaction shares (indirect)0Post-transaction value (direct ownership)$0Transaction value based on SEC Form 4 reported price ($5.69); post-transaction value is $0.00 as of May 18, 2026, since all shares were disposed of.
Key questionsWhat proportion of Insight Holdings Group, LLC’s Coursera position was affected by this transaction?
The sale represented 100% of the reporting entity's indirect holdings in Coursera common stock -- both its indirect position and total reported position were reduced to zero as of May 18, 2026.Did the transaction involve direct or indirect ownership, and what does this imply?
All 78,628 shares were held and sold via indirect ownership. There were no direct holdings before or after the transaction, meaning the entity's exposure was held through affiliated funds or vehicles rather than through a personal or direct account.How does the transaction value relate to Coursera’s trading price at the time?
Shares were sold at approximately $5.69 per share, resulting in a total transaction value of approximately $447,000.Company overviewMetricValueMarket cap$1.5 billionRevenue (TTM)$773.9 millionNet income (TTM)-$63.7 million1-year price change*-37.2%* 1-year price change calculated using June 12, 2026, as the reference date.
Company snapshotCoursera, Inc. is a global online learning platform -- originally launched in 2012 -- that partners with universities and industry leaders to deliver accessible education at scale. As of May 2026, Coursera completed its merger with Udemy, Inc., creating a combined platform serving approximately 290 million learners worldwide.
Offers online courses, professional certificates, degree programs, and enterprise workforce training across disciplines, including data science, business, computer science, and health.Serves individual learners, higher education institutions, and enterprise clients; generates revenue through course enrollments, certification fees, institutional partnerships, and subscription offerings.What this transaction means for investorsGiven the timing of Insight Partners’ sale, this is an interesting transaction. On the surface, seeing an Insight Partners affiliate quietly sell off its entire remaining position is the kind of thing that can make investors nervous. But this is less a vote of no-confidence and more likely a routine portfolio exit by a venture-stage investor that has been unwinding a long-held position over time.
Insight Partners is a technology-focused venture and private equity firm, and Coursera has been in its portfolio since before the company's IPO. Importantly, this filing covers only one entity within the broader Insight Partners family -- Insight Holdings Group, LLC -- which held just 78,628 shares before the sale. Other Insight-affiliated funds continue to hold tens of millions of Coursera shares, as reflected in a separate Form 4 filed the same day. So while this particular entity has fully exited its position, Insight Partners as a whole remains a substantial Coursera shareholder.
What may be more meaningful to long-term investors is what's happening at the company itself. Coursera just completed its merger with Udemy in May 2026, uniting two of the world's largest online learning platforms into a single organization serving roughly 290 million learners and 18,000 enterprise customers. The same day as this filing, Coursera's board announced a $500 million share repurchase program -- a meaningful signal of leadership's confidence in the company's balance sheet and future cash generation. On the financial front, Coursera reported Q1 2026 revenue of approximately $196 million, up 9% year over year, including its fourth consecutive quarter of double-digit growth in the Consumer segment. The company also reaffirmed its full-year 2026 revenue guidance of $805 to $815 million. The Udemy integration brings meaningful scale, though investors will want to watch how smoothly the combined business executes going forward.
For investors, the key takeaway is that this sale reflects one fund exiting a legacy position, not a broader signal that Insight Partners has lost faith in Coursera. Other Insight-affiliated entities continued to hold approximately 28.4 million Coursera shares as reported in a separate filing -- a significant remaining stake by any measure. With the Udemy merger now complete and a $500 million buyback authorized, the more interesting story is how the combined company will perform from here.
Two-year CRENESSITY data in adults showed improvements in cardiometabolic outcomes of insulin resistance, body composition and body weight alongside sustained reductions in glucocorticoid dose Among participants who were overweight or obese at baseline, 37% achieved >5% reduction in body weight at 2 years, and 43% of those with insulin resistance at baseline were no longer insulin resistant at 2 years Favorable trends in bone health outcomes were observed with CRENESSITY treatment, including improvements in bone mineral density with up to 2 years of treatment Patient‑reported survey data from adults in the open-label extension suggested improvements in quality of life outcomes and treatment satisfaction, including emotional well‑being, energy levels and confidence in managing their classic congenital adrenal hyperplasia with CRENESSITY , /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new Phase 3 CAHtalyst® Adult study data demonstrating improved cardiometabolic outcomes alongside sustained glucocorticoid dose reduction through up to two years of treatment with CRENESSITY® (crinecerfont) for classic congenital adrenal hyperplasia. These results, together with additional presentations highlighting improvement in bone outcomes and patient-reported quality of life survey outcomes, were presented at the Endocrine Society's annual meeting, ENDO 2026, in Chicago.
Long-term supraphysiologic glucocorticoid (GC) treatment in adults with classic congenital adrenal hyperplasia (CAH) is associated with obesity, insulin resistance, increased cardiometabolic risk and adverse effects on bone health. In these analyses, adults with classic CAH taking CRENESSITY for up to two years experienced improvements in weight, body composition and insulin resistance, key markers of long-term health, with sustained GC dose reductions and maintenance of baseline androgen control.
"These two-year results provide important evidence on the long-term impact of CRENESSITY for adults living with classic congenital adrenal hyperplasia," said Sanjay Keswani, M.D., Chief Medical Officer, Neurocrine Biosciences. "Sustained improvements across key clinical outcomes, including both cardiometabolic and bone outcomes, underscore the potential of CRENESSITY to meaningfully redefine lifelong disease management and improve health. We are excited to share these new data with the scientific community as we continue to deepen our understanding of the long-term impact of CRENESSITY on patient outcomes and quality of life."
CAHtalyst adult participants (N=182) who completed the 24-week, double-blind, placebo-controlled period and the subsequent six-month, open-label period of the study continued treatment with CRENESSITY in an ongoing open-label extension.
Sustained Improvements in Weight‑related and Metabolic Outcomes over Two Years
Cardiometabolic clinical outcomes were evaluated through up to two years of CRENESSITY treatment, including changes in body weight, body mass index (BMI), body composition and insulin resistance, as assessed by the homeostatic model assessment for insulin resistance (HOMA‑IR) at Months 12 and 24. To avoid potential confounding from glucagon-like peptide-1 (GLP-1) receptor agonists and/or glucose-dependent insulinotropic polypeptide (GIP) use, data from participants taking these medications (n=9) were excluded from the time the medication was started.
Sustained improvements were observed, with mean reductions from baseline in body weight, BMI and insulin resistance.
Among participants who were overweight or obese at baseline, more than one-third achieved clinically meaningful weight loss (>5%) at two years, with reductions in fat mass exceeding changes in lean mass. Improvements in insulin resistance were also sustained through two years, including among participants with insulin resistance at baseline, 43% of whom were no longer insulin resistant at two years. Measure
Baseline
Change
from
Baseline at
Month 12
Change from
Baseline at
Month 24
Mean daily GC dose (mg/m²/day HCe*)
17.6
-6.8
(‑37%)
-7.0
(‑38%)
Mean BMI (kg/m2)†‡
32.5
‑0.9
‑0.9
Percentage of overweight/obese participants who
achieved >5% reduction in weight†‡
—
31%
(35/114)
37%
(35/95)
Change in percent fat mass versus percent lean
mass†‡
—
‑0.9%
versus
+0.7%
‑0.9%
versus
+0.8%
Mean HOMA‑IR‡§
5.3
‑1.5
‑1.7
Percentage of participants who achieved
HOMA-IR ≤2.5‡§
—
40%
(26/65)
43%
(24/56)
*HCe denotes hydrocortisone equivalents.
†Among participants who were overweight or obese (BMI ≥25 kg/m2) at baseline. Clinically meaningful weight loss is defined as >5% reduction in body weight.
‡Data from participants who were taking a GIP/GLP-1 receptor agonist were excluded from the time the medication was started.
§Among participants with insulin resistance (HOMA-IR >2.5) at baseline.
"For many adults with classic congenital adrenal hyperplasia, long‑term supraphysiologic glucocorticoid exposure can contribute to weight gain and insulin resistance, adding to cumulative cardiometabolic burden over time," said Oksana Hamidi, D.O., M.S.C.S., Associate Professor of Internal Medicine, Division of Endocrinology, UT Southwestern Medical Center. "What makes these two-year data particularly meaningful is that they demonstrate sustained glucocorticoid reductions alongside improvements in insulin resistance and body composition, outcomes that are closely tied to future cardiometabolic risk and long-term health."
Favorable Trends Observed Across Bone-related Outcomes
Bone‑related outcomes were also assessed over two years of CRENESSITY treatment, including bone mineral density (BMD) z scores at Months 12, 18 and 24, and mean changes from baseline in bone turnover markers at Months 12 and 18.
Favorable trends were observed in mineral density measurements (lumbar spine and total hip) and bone turnover (formation/resorption).
BMD z scores trended toward incremental improvement over time, with the greatest improvement in the lumbar spine where there is the largest proportion of GC-sensitive bone. All bone turnover markers increased from baseline to Month 12, potentially reflecting recovery from suppression caused by supraphysiologic GC doses. From Month 12 to Month 18, markers of bone formation remained at similar levels, while markers of bone resorption showed a decreasing trend. Patient‑reported Survey Data Reflect Meaningful Changes in Lived Experience
To understand patient perspectives following long‑term CRENESSITY treatment, a cross‑sectional survey was conducted among adult U.S. participants (n=48) at their final open-label extension visit.
In the survey, 96% of respondents indicated they were moderately or very satisfied with their experience with CRENESSITY treatment, and a majority of participants reported:
Having more hope for their future living with classic CAH (98%). Feeling more in control of their classic CAH (94%). Being more optimistic about reducing the long-term impacts of high-dose GCs (96%) and elevated adrenocorticotropic hormone or androgens (92%). Large majorities of participants who experienced improvements also reported those changes as meaningful, including less side effects associated with high-dose steroids (93%) and less worry about weight gain associated with high-dose steroids (81%), as well as high levels of treatment satisfaction, with 98% reporting they would recommend CRENESSITY and 96% reporting they preferred treatment with CRENESSITY over treatment without CRENESSITY.
Across analyses, CRENESSITY was generally well tolerated through up to two years of treatment, with no new safety signals observed during long‑term follow‑up.
These findings build on two‑year data presented earlier this year at the American Association of Clinical Endocrinology 2026 Annual Meeting and the Pediatric Endocrine Society 2026 Annual Meeting in adults and pediatrics, respectively.
Presentations at the ENDO 2026 annual meeting included:
CAHtalyst Adult Study Two-Year Results
Title: Weight-Related Outcomes and Insulin Resistance in Adults with Classic Congenital Adrenal Hyperplasia: 2-Year Results from the CAHtalyst Adult Study (Oral Presentation #ORF32-07)
Authors: Oksana Hamidi, D.O., et al
Title: Adults with Classic Congenital Adrenal Hyperplasia Taking Crinecerfont Demonstrated Sustained Decreases in Glucocorticoid Doses: 2-Year Results from the CAHtalyst Adult Study (Poster Presentation #SUN-458)
Authors: Irina Bancos, M.D., et al
Title: A Cross-sectional Survey on Quality of Life of Adults with Classic Congenital Adrenal Hyperplasia in the United States Participating in CAHtalyst Adult Open-Label Extension Study (Poster Presentation #SUN-467)
Authors: Sonal Vaid, M.D., et al
Title: Bone Outcomes in Adults with Classic Congenital Adrenal Hyperplasia Treated with Crinecerfont for Up to 2 Years in CAHtalyst Adult Study (Poster Presentation #SUN-468)
Authors: Maria Vogiatzi, M.D., et al
CAHtalyst Pediatric Study Two-Year Results
Title: Characterization of Children and Adolescents with Classic Congenital Adrenal Hyperplasia Who Had Slowed Bone Age Progression and Improved Height Prediction with Crinecerfont (Oral Presentation #ORF32-05)
Authors: Maria Vogiatzi, M.D., et al
Title: Long-term Crinecerfont Treatment Reduced ACTH and 17-Hydroxyprogesterone — Clinical Outcomes in Children and Adolescents with Classic Congenital Adrenal Hyperplasia: 2-Year Results from CAHtalyst Pediatric (Poster Presentation #SAT-465)
Authors: Natalie Nokoff, M.D., et al
Title: Long-term Crinecerfont Enables Sustained Decreases in Glucocorticoid Doses — Clinical Outcomes in Children and Adolescents with Classic Congenital Adrenal Hyperplasia: 2-Year Results from CAHtalyst Pediatric (Poster Presentation #SUN-465)
Authors: Kyriakie Sarafoglou, M.D., et al
Additional Presentations
Title: Long-term Risk of Cardiometabolic Comorbidities Associated with Glucocorticoid Exposure and Androgen Control in Classic Congenital Adrenal Hyperplasia: A Cox Proportional Hazards Analysis from the CAHtalog Registry ("New Therapies and Perspectives for Congenital Adrenal Hyperplasia and Adrenal Insufficiency" Rapid Fire Presentation #ORF32-02 and Poster Presentation #MON-495)
Authors: Oksana Lekarev, D.O., et al
Title: Crinecerfont Treatment of Classic Congenital Adrenal Hyperplasia Due to 11β-Hydroxylase Deficiency: A Case Series (Poster Presentation #SAT-466)
Authors: Kyriakie Sarafoglou, M.D., et al
Title: A Modified Delphi Panel of U.S. Endocrinologists to Align on Minimum Clinically Important Difference in Glucocorticoid Dose and Other Key Considerations in Classic Congenital Adrenal Hyperplasia (Poster Presentation #SAT-459)
Authors: Ahmed Khattab, M.D., et al
About Congenital Adrenal Hyperplasia
Congenital adrenal hyperplasia (CAH) is a rare genetic condition that results in an enzyme deficiency that alters the production of adrenal steroid hormones, such as cortisol, aldosterone and adrenal androgens. Severe enzyme deficiency leads to an inability of the adrenal glands to produce enough cortisol and, in approximately 75% of cases, aldosterone. Because individuals with CAH are typically still able to produce androgens, the unused precursors that would normally be used to make cortisol instead result in the production of excess amounts of androgens. If left untreated, CAH can result in adrenal crisis and even death.
Exogenous glucocorticoids (GCs) are necessary to correct the endogenous cortisol deficiency, but historically, doses higher than those needed for cortisol replacement (supraphysiologic) have been used to lower the elevated levels of adrenocorticotropic hormone (ACTH) and adrenal androgens. However, GC treatment at supraphysiologic doses has been associated with serious and significant complications of steroid excess, including metabolic issues such as weight gain and diabetes, cardiovascular disease and osteoporosis. Additionally, long-term treatment with supraphysiologic GCs may have psychological and cognitive impacts, such as changes in mood and memory. Adrenal androgen excess has been associated with abnormal bone growth and development in pediatric patients, female health problems such as excess facial hair growth and menstrual irregularities, in addition to cardiometabolic and fertility issues in both sexes. The symptoms of high ACTH may include testicular adrenal rest tumors (TARTs).
About CRENESSITY® (crinecerfont)
CRENESSITY is a potent and selective oral corticotropin-releasing factor type 1 receptor (CRF1) antagonist that reduces and controls excess adrenocorticotropic hormone (ACTH) and adrenal androgens through a non-glucocorticoid (GC) mechanism for the treatment of classic congenital adrenal hyperplasia (CAH). Antagonism of CRF1 receptors in the pituitary has been shown to decrease ACTH levels, which in turn decreases the production of adrenal androgens and potentially the symptoms associated with CAH. The robust clinical study data demonstrate that lowering adrenal androgen levels with CRENESSITY enables lower, more physiologic dosing of GCs to replace missing cortisol.
CRENESSITY comes in capsules and an oral solution. For adults 18 years of age and older, the recommended dosage is 100 mg twice daily taken orally with a meal. For pediatric patients four to 17 years of age weighing less than 55 kg (121 lbs), the recommended dosage is based on body weight and is administered twice daily, taken orally with a meal. For pediatric patients weighing more than 55 kg (121 lbs), the recommended dosage is 100 mg twice daily taken orally with a meal. Healthcare providers can work with patients to determine the appropriate formulation for use depending on patient needs. Patients receiving CRENESSITY should continue GC therapy for cortisol replacement.
About the CAHtalyst® Studies
The Phase 3 CAHtalyst global registrational studies were designed to evaluate the safety, efficacy and tolerability of CRENESSITY® (crinecerfont) in children and adults with classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency. The CAHtalyst studies were the largest-ever clinical trial program in classic CAH, including 285 pediatric and adult patients.
The CAHtalyst Pediatric study included 103 pediatric patients four to 17 years of age. The study tested two questions. The first question evaluated whether four weeks of CRENESSITY treatment could improve androgen control. The second question evaluated whether an additional 24 weeks of CRENESSITY treatment enabled customized glucocorticoid (GC) down-titration while androstenedione levels were maintained or improved.
The CAHtalyst Adult study included 182 adult patients 18 to 58 years of age. Similarly, the first question of the study evaluated whether four weeks of CRENESSITY treatment could improve androgen control, and the second question evaluated whether an additional 20 weeks of CRENESSITY treatment enabled GC reduction to physiologic range while androstenedione levels were maintained or improved.
Data from the CAHtalyst Phase 3 studies supported approval of CRENESSITY by the U.S. Food and Drug Administration in December 2024. The open-label extension treatment portions of both studies are ongoing.
Important Information
Approved Uses
CRENESSITY® (crinecerfont) is a prescription medicine used together with glucocorticoids (steroids) to control androgen (testosterone-like hormone) levels in adults and children 4 years of age and older with classic congenital adrenal hyperplasia (CAH).
IMPORTANT SAFETY INFORMATION
Do not take CRENESSITY if you:
Are allergic to crinecerfont, or any of the ingredients in CRENESSITY.
CRENESSITY may cause serious side effects, including:
Allergic reactions. Symptoms of an allergic reaction include tightness of the throat, trouble breathing or swallowing, swelling of the lips, tongue, or face, and rash. If you have an allergic reaction to CRENESSITY, get emergency medical help right away and stop taking CRENESSITY.
Risk of Sudden Adrenal Insufficiency or Adrenal Crisis with Too Little Glucocorticoid (Steroid) Medicine. Sudden adrenal insufficiency or adrenal crisis can happen in people with congenital adrenal hyperplasia who are not taking enough glucocorticoid (steroid) medicine. You should continue taking your glucocorticoid (steroid) medicine during treatment with CRENESSITY. Certain conditions such as infection, severe injury, or shock may increase your risk for sudden adrenal insufficiency or adrenal crisis. Tell your healthcare provider if you get a severe injury, infection, illness, or have planned surgery during treatment. Your healthcare provider may need to change your dose of glucocorticoid (steroid) medicine.
Before taking CRENESSITY, tell your healthcare provider about all of your medical conditions, including if you: are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins and herbal supplements.
The most common side effects of CRENESSITY in adults include tiredness, headache, dizziness, joint pain, back pain, decreased appetite, and muscle pain.
The most common side effects of CRENESSITY in children include headache, stomach pain, tiredness, nasal congestion, and nosebleeds.
These are not all the possible side effects of CRENESSITY. Call your healthcare provider for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch at www.fda.gov/medwatch or call 1-800-FDA-1088.
Dosage Forms and Strengths: CRENESSITY is available in 50 mg and 100 mg capsules, and as an oral solution of 50 mg/mL.
Please see full Prescribing Information.
About Neurocrine Biosciences, Inc.
Neurocrine Biosciences is a leading biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering, developing and commercializing life-changing treatments for patients with under-addressed neurological, psychiatric, endocrine and immunological disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, hyperphagia in patients with Prader-Willi syndrome, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For more than three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn, X, Facebook and YouTube. (*in collaboration with AbbVie)
The NEUROCRINE BIOSCIENCES Logo, NEUROCRINE, YOU DESERVE BRAVE SCIENCE, CRENESSITY and CAHtalyst are registered trademarks of Neurocrine Biosciences, Inc.
Forward-Looking Statements
In addition to historical facts, this press release contains forward-looking statements that involve a number of risks and uncertainties. These statements include, but are not limited to, statements regarding the potential benefits to be derived from CRENESSITY for the treatment of classic congenital adrenal hyperplasia (CAH); the value and benefits CRENESSITY brings to patients with CAH, including its potential support sustained glucocorticoid dose reductions and contribute to improvements in certain cardiometabolic, bone health and patient-reported outcomes; the ability of Neurocrine Biosciences to ensure patients have access to CRENESSITY; and whether the results from our clinical trials of CRENESSITY are indicative of real-world results. Factors that could cause actual results to differ materially from those stated or implied in the forward-looking statements include, but are not limited to, the following: risks and uncertainties as to whether the data described in this press release will be replicated in additional studies or will be predictive of efficacy or other clinical outcomes in subsequent clinical studies or real-world use of CRENESSITY; risks and uncertainties associated with Neurocrine Biosciences' business and finances in general, as well as risks and uncertainties associated with the commercialization of CRENESSITY, including the extent to which patients and physicians accept and adopt CRENESSITY; whether CRENESSITY receives adequate reimbursement from third-party payors; risks and uncertainties relating to competitive products and technological changes that may limit demand for CRENESSITY; risks associated with the Company's dependence on third parties for development and manufacturing activities related to CRENESSITY, and the ability of the Company to manage these third parties; risks that additional regulatory submissions for CRENESSITY may not occur or be submitted in a timely manner; risks that the FDA or other regulatory authorities may make adverse decisions regarding CRENESSITY; risks that post-approval CRENESSITY commitments or requirements may be delayed; risks that CRENESSITY may be precluded from commercialization by the proprietary or regulatory rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; risks and uncertainties relating to competitive products and technological changes that may limit demand for CRENESSITY; and other risks described in the Company's periodic reports filed with the Securities and Exchange Commission, including without limitation the Company's quarterly report on Form 10-Q for the quarter ended March 31, 2026. Neurocrine Biosciences disclaims any obligation to update the statements contained in this press release after the date hereof other than required by law.
Two-year data showed that pediatric patients with accelerated bone age at baseline experienced slowed bone age progression and improved predicted adult height with CRENESSITY Cross-sectional caregiver survey data showed universal satisfaction with CRENESSITY, willingness to recommend treatment and increased optimism about their child's future quality of life following treatment initiation , /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new two-year data from the Phase 3 CAHtalyst® Pediatric study showing positive growth outcomes in children and adolescents with classic congenital adrenal hyperplasia treated with CRENESSITY® (crinecerfont). Patients with advanced bone age at baseline experienced slowed bone age progression and improved predicted adult height after two years of treatment. These data were presented at the Endocrine Society's annual meeting, ENDO 2026, in Chicago.
"Treatment decisions made during growth years can have lifelong implications for children and adolescents with classic congenital adrenal hyperplasia," said Sanjay Keswani, M.D., Chief Medical Officer, Neurocrine Biosciences. "Excess adrenal androgens can accelerate bone maturation and limit adult height. These two‑year data suggest that sustained androgen control with CRENESSITY, combined with reduced glucocorticoid exposure, may help address abnormal growth in pediatric patients by slowing the advancement of bone age and narrowing the gap between bone age and chronological age."
Pediatric participants who completed the 28‑week, double‑blind, placebo‑controlled period and the subsequent six‑month, open‑label period of the CAHtalyst Pediatric study continued treatment with CRENESSITY in an ongoing, open‑label extension.
Slowed Bone Age Progression and Improved Predicted Adult Height
In the subset of growing pediatric patients (n=41), changes in bone age and predicted adult height were evaluated at Month 24. Bone age was assessed using bone age standard deviation score (SDS), a measure that compares skeletal maturity to age- and sex-matched norms.
Among those with advanced bone age at baseline (n=24), bone age SDS remained stable or improved in most patients with up to two years of CRENESSITY treatment. Mean bone age SDS decreased by 1.12, with a subset of patients (n=9) demonstrating reductions greater than two standard deviations. In this subset of patients, mean predicted adult height increased by 4.7 cm from baseline. Together the data suggest that sustained hormonal control and substantial glucocorticoid (GC) reductions enabled by CRENESSITY may positively influence growth during childhood and adolescence.
"Accelerated bone age is one of the most challenging complications we face when managing classic congenital adrenal hyperplasia in growing children because it can permanently affect adult height," said Maria G. Vogiatzi, M.D., Division of Endocrinology at Children's Hospital of Philadelphia, Principal Investigator for the CAHtalyst Pediatric study and lead author of the growth analysis. "Seeing stabilization and even improvement in bone age over two years in a subset of patients is encouraging and suggests meaningful progress in addressing a key driver of compromised growth during the critical development years."
Caregiver-reported Survey Data Reflects Satisfaction with CRENESSITY and Increased Optimism
To further explore caregiver perspectives and patient experience following long-term treatment with CRENESSITY, a cross-sectional, caregiver-reported survey of eligible U.S. participants from the CAHtalyst Pediatric open-label extension (n=29; preliminary analysis) was conducted at patients' latest site visits.
Among caregivers in the preliminary survey analysis, 100% (29/29) reported:
Overall satisfaction with CRENESSITY. Likelihood to recommend CRENESSITY to others with classic congenital adrenal hyperplasia (CAH). Increased optimism about reducing risks of long-term impacts associated with high-dose steroid use, including 79% (23/29) who reported feeling less concern about steroid-associated weight gain. Nearly all respondents (97%, 28/29) reported greater overall hope for their child's future living with classic CAH, with 93% (27/29) indicating increased optimism about reducing long-term impact of high levels of adrenocorticotropic hormone and androgens.
Across analyses, CRENESSITY was generally well tolerated through two years of treatment in pediatric patients, with no new safety signals observed during long‑term follow‑up.
These analyses build on previously presented results showing that CRENESSITY enabled substantial, sustained reductions in mean GC dose over two years without compromising androgen control. Reduced GC exposure was associated with sustained improvements in clinical outcomes linked to long‑term, supraphysiologic GC use, including insulin resistance, weight and body mass index. These findings suggest a reduction in cardiometabolic risk in pediatric patients with classic CAH.
Presentations at the ENDO 2026 annual meeting included:
CAHtalyst Adult Study Two-Year Results
Title: Weight-Related Outcomes and Insulin Resistance in Adults with Classic Congenital Adrenal Hyperplasia: 2-Year Results from the CAHtalyst Adult Study (Oral Presentation #ORF32-07)
Authors: Oksana Hamidi, D.O., et al
Title: Adults with Classic Congenital Adrenal Hyperplasia Taking Crinecerfont Demonstrated Sustained Decreases in Glucocorticoid Doses: 2-Year Results from the CAHtalyst Adult Study (Poster Presentation #SUN-458)
Authors: Irina Bancos, M.D., et al
Title: A Cross-sectional Survey on Quality of Life of Adults with Classic Congenital Adrenal Hyperplasia in the United States Participating in CAHtalyst Adult Open-Label Extension Study (Poster Presentation #SUN-467)
Authors: Sonal Vaid, M.D., et al
Title: Bone Outcomes in Adults with Classic Congenital Adrenal Hyperplasia Treated with Crinecerfont for Up to 2 Years in CAHtalyst Adult Study (Poster Presentation #SUN-468)
Authors: Maria Vogiatzi, M.D., et al
CAHtalyst Pediatric Study Two-Year Results
Title: Characterization of Children and Adolescents with Classic Congenital Adrenal Hyperplasia Who Had Slowed Bone Age Progression and Improved Height Prediction with Crinecerfont (Oral Presentation #ORF32-05)
Authors: Maria Vogiatzi, M.D., et al
Title: Long-term Crinecerfont Treatment Reduced ACTH and 17-Hydroxyprogesterone — Clinical Outcomes in Children and Adolescents with Classic Congenital Adrenal Hyperplasia: 2-Year Results from CAHtalyst Pediatric (Poster Presentation #SAT-465)
Authors: Natalie Nokoff, M.D., et al
Title: Long-term Crinecerfont Enables Sustained Decreases in Glucocorticoid Doses — Clinical Outcomes in Children and Adolescents with Classic Congenital Adrenal Hyperplasia: 2-Year Results from CAHtalyst Pediatric (Poster Presentation #SUN-465)
Authors: Kyriakie Sarafoglou, M.D., et al
Additional Presentations
Title: Long-Term Risk of Cardiometabolic Comorbidities Associated with Glucocorticoid Exposure and Androgen Control in Classic Congenital Adrenal Hyperplasia: A Cox Proportional Hazards Analysis from the CAHtalog Registry ("New Therapies and Perspectives for Congenital Adrenal Hyperplasia and Adrenal Insufficiency" Rapid Fire Presentation #ORF32-02 and Poster Presentation #MON-495)
Authors: Oksana Lekarev, D.O., et al
Title: Crinecerfont Treatment of Classic Congenital Adrenal Hyperplasia Due to 11β-Hydroxylase Deficiency: A Case Series (Poster Presentation #SAT-466)
Authors: Kyriakie Sarafoglou, M.D., et al
Title: A Modified Delphi Panel of U.S. Endocrinologists to Align on Minimum Clinically Important Difference in Glucocorticoid Dose and Other Key Considerations in Classic Congenital Adrenal Hyperplasia (Poster Presentation #SAT-459)
Authors: Ahmed Khattab, M.D., et al
About Congenital Adrenal Hyperplasia
Congenital adrenal hyperplasia (CAH) is a rare genetic condition that results in an enzyme deficiency that alters the production of adrenal steroid hormones, such as cortisol, aldosterone and adrenal androgens. Severe enzyme deficiency leads to an inability of the adrenal glands to produce enough cortisol and, in approximately 75% of cases, aldosterone. Because individuals with CAH are typically still able to produce androgens, the unused precursors that would normally be used to make cortisol instead result in the production of excess amounts of androgens. If left untreated, CAH can result in adrenal crisis and even death.
Exogenous glucocorticoids (GCs) are necessary to correct the endogenous cortisol deficiency, but historically, doses higher than those needed for cortisol replacement (supraphysiologic) have been used to lower the elevated levels of adrenocorticotropic hormone (ACTH) and adrenal androgens. However, GC treatment at supraphysiologic doses has been associated with serious and significant complications of steroid excess, including metabolic issues such as weight gain and diabetes, cardiovascular disease and osteoporosis. Additionally, long-term treatment with supraphysiologic GCs may have psychological and cognitive impacts, such as changes in mood and memory. Adrenal androgen excess has been associated with abnormal bone growth and development in pediatric patients, female health problems such as excess facial hair growth and menstrual irregularities, in addition to cardiometabolic and fertility issues in both sexes. The symptoms of high ACTH may include testicular adrenal rest tumors (TARTs).
About CRENESSITY® (crinecerfont)
CRENESSITY is a potent and selective oral corticotropin-releasing factor type 1 receptor (CRF1) antagonist that reduces and controls excess adrenocorticotropic hormone (ACTH) and adrenal androgens through a non-glucocorticoid (GC) mechanism for the treatment of classic congenital adrenal hyperplasia (CAH). Antagonism of CRF1 receptors in the pituitary has been shown to decrease ACTH levels, which in turn decreases the production of adrenal androgens and potentially the symptoms associated with CAH. The robust clinical study data demonstrate that lowering adrenal androgen levels with CRENESSITY enables lower, more physiologic dosing of GCs to replace missing cortisol.
CRENESSITY comes in capsules and an oral solution. For adults 18 years of age and older, the recommended dosage is 100 mg twice daily taken orally with a meal. For pediatric patients four to 17 years of age weighing less than 55 kg (121 lbs), the recommended dosage is based on body weight and is administered twice daily, taken orally with a meal. For pediatric patients weighing more than 55 kg (121 lbs), the recommended dosage is 100 mg twice daily taken orally with a meal. Healthcare providers can work with patients to determine the appropriate formulation for use depending on patient needs. Patients receiving CRENESSITY should continue GC therapy for cortisol replacement.
About the CAHtalyst® Studies
The Phase 3 CAHtalyst global registrational studies were designed to evaluate the safety, efficacy and tolerability of CRENESSITY® (crinecerfont) in children and adults with classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency. The CAHtalyst studies were the largest-ever clinical trial program in classic CAH, including 285 pediatric and adult patients.
The CAHtalyst Pediatric study included 103 pediatric patients four to 17 years of age. The study tested two questions. The first question evaluated whether four weeks of CRENESSITY treatment could improve androgen control. The second question evaluated whether an additional 24 weeks of CRENESSITY treatment enabled customized glucocorticoid (GC) down-titration while androstenedione levels were maintained or improved.
The CAHtalyst Adult study included 182 adult patients 18 to 58 years of age. Similarly, the first question of the study evaluated whether four weeks of CRENESSITY treatment could improve androgen control, and the second question evaluated whether an additional 20 weeks of CRENESSITY treatment enabled GC reduction to physiologic range while androstenedione levels were maintained or improved.
Data from the CAHtalyst Phase 3 studies supported approval of CRENESSITY by the U.S. Food and Drug Administration in December 2024. The open-label extension treatment portions of both studies are ongoing.
Important Information
Approved Uses
CRENESSITY® (crinecerfont) is a prescription medicine used together with glucocorticoids (steroids) to control androgen (testosterone-like hormone) levels in adults and children 4 years of age and older with classic congenital adrenal hyperplasia (CAH).
IMPORTANT SAFETY INFORMATION
Do not take CRENESSITY if you:
Are allergic to crinecerfont, or any of the ingredients in CRENESSITY.
CRENESSITY may cause serious side effects, including:
Allergic reactions. Symptoms of an allergic reaction include tightness of the throat, trouble breathing or swallowing, swelling of the lips, tongue, or face, and rash. If you have an allergic reaction to CRENESSITY, get emergency medical help right away and stop taking CRENESSITY.
Risk of Sudden Adrenal Insufficiency or Adrenal Crisis with Too Little Glucocorticoid (Steroid) Medicine. Sudden adrenal insufficiency or adrenal crisis can happen in people with congenital adrenal hyperplasia who are not taking enough glucocorticoid (steroid) medicine. You should continue taking your glucocorticoid (steroid) medicine during treatment with CRENESSITY. Certain conditions such as infection, severe injury, or shock may increase your risk for sudden adrenal insufficiency or adrenal crisis. Tell your healthcare provider if you get a severe injury, infection, illness, or have planned surgery during treatment. Your healthcare provider may need to change your dose of glucocorticoid (steroid) medicine.
Before taking CRENESSITY, tell your healthcare provider about all of your medical conditions, including if you: are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins and herbal supplements.
The most common side effects of CRENESSITY in adults include tiredness, headache, dizziness, joint pain, back pain, decreased appetite, and muscle pain.
The most common side effects of CRENESSITY in children include headache, stomach pain, tiredness, nasal congestion, and nosebleeds.
These are not all the possible side effects of CRENESSITY. Call your healthcare provider for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch at www.fda.gov/medwatch or call 1-800-FDA-1088.
Dosage Forms and Strengths: CRENESSITY is available in 50 mg and 100 mg capsules, and as an oral solution of 50 mg/mL.
Please see full Prescribing Information.
About Neurocrine Biosciences, Inc.
Neurocrine Biosciences is a leading biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering, developing and commercializing life-changing treatments for patients with under-addressed neurological, psychiatric, endocrine and immunological disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, hyperphagia in patients with Prader-Willi syndrome, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For more than three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn, X, Facebook and YouTube. (*in collaboration with AbbVie)
The NEUROCRINE BIOSCIENCES Logo, NEUROCRINE, YOU DESERVE BRAVE SCIENCE, CRENESSITY and CAHtalyst are registered trademarks of Neurocrine Biosciences, Inc.
Forward-Looking Statements
In addition to historical facts, this press release contains forward-looking statements that involve a number of risks and uncertainties. These statements include, but are not limited to, statements regarding the potential benefits to be derived from CRENESSITY for the treatment of classic congenital adrenal hyperplasia (CAH); the value and benefits CRENESSITY brings to patients with CAH, including its potential to help address abnormal growth in pediatric patients with CAH by slowing bone age progression and improving predicted adult height in patients with advanced bone age at baseline; the ability of Neurocrine Biosciences to ensure patients have access to CRENESSITY; and whether the results from our clinical trials of CRENESSITY are indicative of real-world results. Factors that could cause actual results to differ materially from those stated or implied in the forward-looking statements include, but are not limited to, the following: risks and uncertainties as to whether the data described in this press release will be replicated in additional studies or will be predictive of efficacy or other clinical outcomes in subsequent clinical studies or real-world use of CRENESSITY; risks and uncertainties associated with Neurocrine Biosciences' business and finances in general, as well as risks and uncertainties associated with the commercialization of CRENESSITY, including the extent to which patients and physicians accept and adopt CRENESSITY; whether CRENESSITY receives adequate reimbursement from third-party payors; risks and uncertainties relating to competitive products and technological changes that may limit demand for CRENESSITY; risks associated with the Company's dependence on third parties for development and manufacturing activities related to CRENESSITY, and the ability of the Company to manage these third parties; risks that additional regulatory submissions for CRENESSITY may not occur or be submitted in a timely manner; risks that the FDA or other regulatory authorities may make adverse decisions regarding CRENESSITY; risks that post-approval CRENESSITY commitments or requirements may be delayed; risks that CRENESSITY may be precluded from commercialization by the proprietary or regulatory rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; risks and uncertainties relating to competitive products and technological changes that may limit demand for CRENESSITY; and other risks described in the Company's periodic reports filed with the Securities and Exchange Commission, including without limitation the Company's quarterly report on Form 10-Q for the quarter ended March 31, 2026. Neurocrine Biosciences disclaims any obligation to update the statements contained in this press release after the date hereof other than required by law.
Filing represents another important step in advancing Coosa, the largest and most developed graphite deposit in the contiguous United States
CENTENNIAL, Colo.--(BUSINESS WIRE)--Westwater Resources, Inc. (NYSE American: WWR), an energy technology and battery-grade natural graphite company (“Westwater” or the “Company”), today announced that it has submitted a Section 404 permit application to the U.S. Army Corps of Engineers for the Company’s Coosa Graphite Deposit in Coosa County, Alabama.
“Submission of the Section 404 permit application reflects continued progress in advancing Coosa through the permitting process,” said Frank Bakker, President and Chief Executive Officer of Westwater Resources.
Share The Section 404 permit application, submitted under the Clean Water Act, represents an important step in the permitting process for Coosa. The application relates to certain potential impacts to water associated with future development activities at the project site.
“Submission of the Section 404 permit application reflects continued progress in advancing Coosa through the permitting process,” said Frank Bakker, President and Chief Executive Officer of Westwater Resources. “Coosa is intended to serve as a future domestic feedstock source for our Kellyton Graphite Plant, supporting our objective of developing a secure U.S. vertically-integrated supply of battery-grade graphite.”
The Section 404 application follows the Company’s previously announced permit application filed earlier this year with the Alabama Department of Environmental Management (“ADEM”). Together, these permitting steps support Westwater’s continued advancement of Coosa through environmental review and permitting.
Coosa is listed on the federal FAST-41 Permitting Dashboard, which provides a publicly available timetable for environmental review and permitting activities. Westwater expects to continue advancing Coosa in alignment with the FAST-41 process and currently anticipates evaluating a final investment decision for the Coosa project following completion of the broader permitting process.
The Coosa Graphite Deposit is located approximately 30 miles from Westwater’s Kellyton Graphite Plant in east-central Alabama. Coosa is the largest and most developed graphite deposit in the contiguous United States and will provide a long-term domestic source of natural flake graphite feedstock, while Kellyton is being developed to process natural flake graphite into battery-grade graphite. Together, these assets support Westwater’s vertically-integrated, mine-to-market strategy of developing U.S.-based graphite production capacity for domestic battery supply chains.
About Westwater Resources, Inc.
Westwater Resources, Inc. (NYSE American: WWR) is a critical minerals and energy technology company advancing a vertically integrated, mine-to-market platform for battery-grade natural graphite in the United States. The Company’s platform is anchored by the Coosa Graphite Deposit in Alabama, the largest natural flake graphite deposit in the contiguous United States, and the Kellyton Graphite Plant, a processing facility designed to produce coated spherical purified graphite (CSPG), a key material used in lithium-ion battery anodes. For more information, visit WestwaterResources.com.
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to risks, uncertainties and assumptions and are identified by words and phrases such as “important step,” “advancing,” “largest and most developed,” “potential impacts,” “future development,” “continued progress,” “intended to serve,” “continued advancement,” “expects,” “continued advancing,” “currently anticipates,” “will provide,” “designed to produce,” and other similar words and phrases. Forward looking statements include, among other things, statements concerning operational developments including the construction of the Kellyton Graphite Plant, the development of the Coosa Graphite Deposit and its inclusion on the federal FAST-41 dashboard, and the costs, schedules, production and economic projections associated with both of them. The Company cautions that there are factors that could cause actual results to differ materially from the forward-looking information that has been provided.
The reader is cautioned not to put undue reliance on this forward-looking information, which is not a guarantee of future performance and is subject to a number of uncertainties and other factors, many of which are outside the control of the Company; accordingly, there can be no assurance that such suggested results will be realized. Those uncertainties and other factors are discussed in Westwater’s Annual Report on Form 10-K for the year ended December 31, 2025, and subsequent securities filings, and they could cause actual results to differ materially from management expectations.
LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--Zebra Technologies Corporation (NASDAQ: ZBRA), a global leader in digitizing and automating workflows to deliver intelligent operations, today announced its inclusion in the Wall Street Journal's inaugural Best Companies for the Future report. Zebra was ranked 10th in the category of AI readiness and 76th overall among S&P 500 companies. “We are proud to be recognized as a leader in the next era of AI-driven innovation,” said Tom Bianculli, Chief Technol.
Warren Buffett stepped down as CEO of Berkshire Hathaway (NYSE: BRK-B | BRK-B Price Prediction) on December 31, 2025, after six decades leading the conglomerate he transformed from a struggling textile mill into a $1 trillion empire. The “Oracle of Omaha” left his successor, Greg Abel, with a very concentrated portfolio: 70% of Berkshire’s $381 billion portfolio is invested in just seven stocks. Abel, who has served as vice chair overseeing non-insurance operations, officially took over as CEO on January 1, 2026. At 95 years old, Buffett isn’t fully retiring—he will remain chair of the board and plans to continue coming to the Omaha headquarters as much as before. However, he has stated he will be “going quiet” and leaving all decision-making to Abel.
One thing is for sure: the new CEO got to work in the first quarter, and 16 companies were eliminated, leaving just 26 stocks in the Berkshire Hathaway portfolio. In addition, Abel stunned the world as the company made its first major acquisition of a publicly traded company in years, buying homebuilder Taylor Morrison (NYSE: TMHC). The deal was priced at $72.50 per share in an all-cash transaction, implying an equity value of $6.8 billion and an enterprise value of $8.5 billion, including the homebuilder’s net debt. The agreement, one of the first major acquisitions under Abel, delivers a 24% premium to the target’s prior stock price. It is expected to close in the second half of the year, with Taylor Morrison continuing to operate under its existing management team. Before Taylor Morrison, the company’s last major buyout of an entire publicly traded company was Alleghany, which was acquired for $11.6 billion in 2022.
After the portfolio purge and the first acquisition since the purchase of OxyChem from Occidental Petroleum, just four stocks now make up 53.8% of the Berkshire Hathaway portfolio. Of the four stocks, only one saw any selling in the first quarter. However, the sale was quite minor, reducing their massive investment by less than 1%.
Why do we cover Berkshire Hathaway stocks? Few investors have the results and reputation that Buffett has garnered over the past 60 years. Though he has stepped away from the CEO chair, his impact and investment guidelines are likely to remain in place long after he is gone. While investing has evolved since Buffett took control of Berkshire Hathaway in 1965, buying good companies with products and services recognized worldwide and paying dividends will always remain a timeless approach.
Here are the four companies that now make up 53.8% of Berkshire Hathaway. All are rated Buy at top Wall Street firms we cover.
American Express American Express (NYSE: AXP) is an American bank holding company and multinational financial services corporation specializing in payment cards. The stock pays a dividend yield of 1.07%. American Express is a globally integrated payments company operating card-issuing, merchant-acquiring, and card network businesses.
The company offers products and services to customers worldwide, including consumers, small businesses, mid-sized companies, and large corporations. Its segments include:
U.S. Consumer Services, which offers travel and lifestyle services, as well as banking and non-card financing products. Commercial Services offers payment, expense management, banking, and non-card financing products. International Card Services provides services to international customers, including travel and lifestyle services, and manages certain international joint ventures and its loyalty coalition business. Global Merchant and Network Services operates a payments network that processes and settles card transactions, acquires merchants, and provides multichannel marketing programs, capabilities, services, and data analytics. Berkshire Hathaway owns 151,610,700 shares, 22% of American Express’s float and 14.2% of the portfolio.
Goldman Sachs has a Buy rating with a $400 target price.
Apple Apple (NASDAQ: AAPL) designs, develops, and sells consumer electronics, computer software, and online services, offering a small dividend of 0.35%. It is almost incomprehensible that the legacy technology giant, even after a recent fourth-quarter sale of 10 million shares and a surge in sales over the past two years, still holds a 227,917,808-share position that accounts for 21.8% of the Berkshire Hathaway portfolio, which holds 1.6% of Apple’s stock.
The company offers:
The iPhone, a line of smartphones Mac, a line of personal computers iPad, a line of multi-purpose tablets Wearables, home, and accessories comprising AirPods, Apple TV, Apple Watch, Beats products, and HomePod Apple also offers AppleCare support and cloud services, and operates various platforms, including the App Store, which enables customers to discover and download applications and digital content, such as books, music, videos, games, and podcasts.
In addition, the company offers various services, such as:
Apple Arcade, a game subscription service Apple Fitness+, a personalized fitness service Apple Music, which gives users a curated listening experience with on-demand radio stations Apple News+, a subscription news and magazine service Apple TV+, which offers exclusive original content Apple Card, a co-branded credit card Apple Pay, a cashless payment service Wedbush has an Outperform rating with a $400 target price.
Bank of America While Buffett trimmed his position in a big way over the past two years, this quality financial giant remains an exceptional long-term holding with a solid 2% dividend yield. Bank of America (NYSE: BAC) is a bank holding company that reported impressive Q4 results. Berkshire Hathaway owns 513,624,165 shares, which is 8.3% of the portfolio and 7.2% of the float. Berkshire did lower its Bank of America position in Q1 2026, but only modestly. According to the Q1 2026 13F filing, it was reduced by just 0.71%, a tiny cut compared to other positions.
Its segments include:
Consumer Banking offers a range of credit, banking, and investment products and services to consumers and small businesses. Global Wealth & Investment Management (GWIM) comprises two businesses: Merrill Wealth Management, which offers tailored solutions to meet clients’ needs through a comprehensive suite of investment management, brokerage, banking, and retirement products. Bank of America Private Bank provides comprehensive wealth management solutions. Global Banking offers a range of lending-related products and services, including integrated working capital management and treasury solutions, as well as underwriting and advisory services. Global Markets offers sales and trading services, as well as research services, to institutional clients across fixed income, credit, currency, commodity, and equity markets. UBS has a Buy rating with a $63 target price.
Coca-Cola Coca-Cola (NYSE: KO) is an American multinational corporation founded in 1892. This company remains a top long-time holding of Buffett. Berkshire owns 400 million shares, representing 9.3% of the float and 9.7% of the portfolio. The stock pays a dependable 2.46% dividend.
Coca-Cola is the world’s largest beverage company, offering consumers more than 500 sparkling and still brands. Led by Coca-Cola, one of the world’s most valuable and recognizable brands, the portfolio features 20 billion-dollar brands, including:
Diet Coke Coca-Cola Light Coca-Cola Zero Sugar Caffeine-free Diet Coke Cherry Coke Fanta Orange Fanta Zero Orange Fanta Zero Sugar Fanta Apple Sprite Sprite Zero Sugar Simply Orange Simply Apple Simply Grapefruit Fresca Schweppes Dasani Fuze Tea Glacéau Smartwater Glacéau Vitaminwater Gold Peak Ice Dew Powerade Topo Chico Minute Maid Globally, it is the top provider of sparkling beverages, ready-to-drink coffees, juices, and juice drinks. Through the world’s most extensive beverage distribution system, consumers in more than 200 countries enjoy the company’s beverages at a rate of over 1.9 billion servings per day. And remember that the company owns 19.5% of Monster Beverage (NASDAQ: MNST), which continues to deliver strong financial results.
Citigroup has a Buy rating with a $91 target price.
Ryan Yost appointed Division President, Global Flexible Packaging Solutions
Kate Pearlman appointed Senior Vice President, Investor Relations & Treasury
, /PRNewswire/ -- Amcor (NYSE: AMCR, ASX: AMC), a global leader in developing and producing responsible packaging solutions, today announced the appointments of Ryan Yost as Division President, Global Flexible Packaging Solutions, and Kate Pearlman as Senior Vice President, Investor Relations & Treasury.
Ryan Yost joins Amcor as Division President, Global Flexible Packaging Solutions.
Kate Pearlman joins Amcor as Senior Vice President, Investor Relations & Treasury. With 25 years of leadership roles at Avery Dennison, Ryan brings proven success in delivering consistent, profitable organic growth, most recently as President of Avery Dennison's global $6 billion Materials Group. He previously held various senior leadership roles spanning commercial, operations, supply chain and material science responsibilities. Ryan will accelerate Amcor's organic growth strategy across the Global Flexible Packaging Solutions platform, building on the business' leadership positions in attractive end markets including healthcare, protein, pet food, liquids, beauty and personal care and food service. He will be based in the U.S.
Kate has more than 20 years of experience in investor relations, global treasury and risk management leadership at Fortune 200 companies. She joins Amcor from Lowe's, where she held the role of Vice President, Investor Relations and Treasurer. Kate will lead Amcor's global investor relations function and will also assume responsibility for Amcor's treasury operations. In this expanded role, she will strengthen alignment across capital market management, value creation and shareholder engagement. Kate will report to Stephen Scherger, Executive Vice President and Chief Financial Officer, and the role will be based in the U.S.
"Ryan and Kate are exceptional leaders with proven track records of driving growth, building high-performing teams and translating strategy into results across large, global organizations," said Peter Konieczny, Amcor Chief Executive Officer. "I am highly confident in Amcor's business, strategy and ability to deliver for our customers and shareholders. Ryan and Kate bring the right expertise to help us build momentum, and we're excited to welcome them as we position Amcor for its next phase of growth."
Ryan succeeds Fred Stephan, who is retiring from Amcor, and Kate succeeds Tracey Whitehead, who has chosen to remain in Australia and pursue opportunities there. Fred and Tracey will remain with Amcor as advisors through Dec. 31, 2026, to ensure a smooth transition.
"Fred and Tracey have each made a lasting impact on Amcor, and I thank them for their outstanding leadership, partnership and unwavering commitment to the company," Peter said. "Fred has been instrumental in strengthening our global flexibles business and positioning the business for continued strong performance, while Tracey has served as a highly respected and trusted leader in our engagement with the investment community."
About Amcor
Amcor is the global leader in developing and producing responsible consumer packaging and dispensing solutions across a variety of materials for nutrition, health, beauty and wellness categories. Our global product innovation and sustainability expertise enables us to solve packaging challenges around the world every day, producing a range of flexible packaging, rigid packaging, cartons and closures that are more sustainable, functional and appealing for our customers and their consumers. We are guided by our purpose of elevating customers, shaping lives and protecting the future. Supported by a commitment to safety, over 75,000 people generate $23 billion in annualized sales from operations that span over 400 locations in more than 40 countries. NYSE: AMCR; ASX: AMC
www.amcor.com | LinkedIn | YouTube
Developed in partnership with Club Med, the project will bring the global hospitality brand’s signature all-inclusive experience back to U.S. shores while expanding VICI's experiential real estate portfolio.
ST. CROIX, U.S. Virgin Islands & NEW YORK--(BUSINESS WIRE)--Club Med, the pioneer of the all-inclusive concept with nearly 60 resorts in some of the world’s most desired vacation destinations, and VICI Properties Inc. (NYSE: VICI), an S&P 500 experiential real estate investment trust, announced today the acquisition and planned redevelopment of the iconic Carambola Beach Resort, located in the U.S. Virgin Islands, marking the return of Club Med to U.S. shores. The future Club Med St. Croix will reinforce the hospitality brand’s leadership in the premium all-inclusive category, while bringing a renewed spirit to the destination’s most historic beachfront property.
The project is a result of a partnership between Club Med and VICI. Following VICI’s acquisition of the Carambola Beach Resort, VICI has entered into a long-term triple-net lease with Club Med, and will fund the resort’s redevelopment, elevating the property to Club Med’s Exclusive Collection standards. Club Med will run the future operations of the historic 150-key resort, transforming it into a model for sustainable, culturally rich and all-inclusive hospitality in the region.
“The U.S. Virgin Islands represent an exciting new chapter for Club Med,” said Carolyne Doyon, President and CEO of Club Med North America and the Caribbean. “For more than seven decades, we’ve welcomed North American travelers to our destinations around the world, and now we’re bringing that experience back home. With St. Croix’s natural beauty, strong community spirit, and deep cultural roots, together with the longstanding legacy of this hotel, this project reflects our vision for thoughtful growth, and meaningful connection across the Americas.”
John Payne, President and COO of VICI, said, "We are very excited to begin our partnership with Club Med, a true pioneer of the premium all-inclusive resort experience and the brand leader in the category. Club Med's approach to growth aligns directly with how VICI partners with best-in-class experiential operators, and Carambola Beach Resort is an ideal asset to launch our relationship. We have tremendous respect for what the Club Med team has built, and we look forward to opportunities to support their continued growth across North America for years to come.”
An Iconic Setting Reimagined
Originally built in 1986 by philanthropist and conservation pioneer Laurance Rockefeller, Carambola Beach Resort reflects his enduring vision for the U.S. Virgin Islands, where hospitality and preservation exist in balance. Club Med’s redevelopment plans envision a comprehensive renovation that preserves the property’s natural beauty and historic roots.
The resort, nestled between a crescent beach and tropical rainforest, will be part of Club Med’s Exclusive Collection, the brand’s most refined portfolio of premium all-inclusive resorts, distinguished by elevated design, personalized service, and exceptional experiences in extraordinary settings.
A Flagship Destination and a U.S. Homecoming
Club Med St. Croix will mark the brand’s reentry onto U.S. soil and aims to attract travelers from the U.S., Canada, and around the world seeking a high quality, all-inclusive experience in a unique island setting. Beyond its touristic appeal, the resort will act as a key economic driver for St. Croix and the broader Virgin Islands, fueling job creation, local partnerships, and sustainable growth across the territory.
Empowering Local Opportunity: Economic Impact
Discussions with senior government officials have highlighted shared ambitions around local employment, education and training, business development, and responsible tourism.
Aligned with Club Med’s Happy to Care sustainability commitments, the project will target BREEAM and Green Globe certifications—benchmarks of environmental design and operational responsibility. Together, these efforts underscore Club Med’s longstanding focus on environmental performance and community stewardship.
“The arrival of the Club Med brand to the U.S. Virgin Islands marks another significant milestone in the continued economic growth and revitalization of our islands — particularly St. Croix — where tourism remains a key driver of opportunity and investment,” said Governor Albert Bryan Jr. “We are proud to welcome the Club Med team to the territory and look forward to growing this partnership as we continue elevating the U.S. Virgin Islands, celebrating our people and culture, and welcoming new and returning visitors to our beautiful shores.”
Once complete, the redevelopment is projected to generate approximately 200 direct jobs along with at least as many indirect opportunities. The resort is expected to further stimulate the local economy through collaborations with excursion operators, service providers, and local farmers and artisans, reinforcing the connection between tourism and the island’s broader community. Club Med plans to continue to engage with the local community in the upcoming months to share further details of the project.
Construction is expected to begin in summer 2026, followed by a targeted reopening in Q4 2027.
To learn more about Club Med’s existing footprint in North America, click here.
About Club Med
Club Med, founded in 1950 by Gérard Blitz, is the pioneer of the all-inclusive concept, operating nearly 60 premium resorts in stunning locations around the world including North and South America, Caribbean, Asia, Africa, Europe and the Mediterranean. Each Club Med resort features authentic local style and comfortably upscale accommodations, superior sports programming and activities, enriching children's programs, gourmet dining, and warm and friendly service by its world-renowned staff with legendary hospitality skills, an all-encompassing energy and diverse backgrounds.
Club Med operates in 40 countries spanning across 5 continents and continues to maintain its authentic Club Med spirit with an international staff of more than 23,000 employees from more than 110 different nationalities. Led by its pioneering spirit, Club Med continues to grow and adapt to each market with three to five new resort openings or renovations per year, including a new mountain resort annually.
For more information, visit www.clubmed.us, call 1-800-Club-Med (1-800-258-2633), or contact a preferred travel professional. For an inside look at Club Med, follow Club Med on Facebook, Instagram, and YouTube.
About VICI Properties Inc.
VICI Properties Inc. is an S&P 500® experiential real estate investment trust that owns one of the largest portfolios of market-leading gaming, hospitality, wellness, entertainment and leisure destinations, including Caesars Palace Las Vegas, MGM Grand and the Venetian Resort Las Vegas, three of the most iconic entertainment facilities on the Las Vegas Strip. VICI Properties owns 101 experiential assets across a geographically diverse portfolio consisting of 61 gaming properties and 40 other experiential properties across the United States and Canada. The portfolio is comprised of approximately 130 million square feet and features over 66,000 hotel rooms and over 700 restaurants, bars, nightclubs and sportsbooks. Its properties are occupied by industry-leading gaming, leisure and hospitality operators under long-term, triple-net lease agreements. VICI Properties has a growing array of real estate and financing partnerships with leading operators in other experiential sectors, including Cabot, Cain, Canyon Ranch, Chelsea Piers, Club Med, Great Wolf Resorts, Homefield, Kalahari Resorts and Lucky Strike Entertainment. VICI Properties also owns four championship golf courses and approximately 33 acres of undeveloped and underdeveloped land adjacent to the Las Vegas Strip. VICI Properties’ goal is to create the highest quality and most productive experiential real estate portfolio through a strategy of partnering with the highest quality experiential place makers and operators. For additional information, please visit www.viciproperties.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws. You can identify these statements by our use of the words “assumes,” “believes,” “estimates,” “expects,” “guidance,” “intends,” “plans,” “projects,” “will,” and similar expressions that do not relate to historical matters. All statements other than statements of historical fact are forward-looking statements. You should exercise caution in interpreting and relying on forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, which are, in some cases, beyond VICI’s control and could materially affect VICI’s actual results, performance, achievements, or VICI’s ability to achieve the benefits contemplated by the transaction. Other important risk factors that may affect VICI’s business, results of operations and financial position (including risks relating to VICI’s pending transactions) are detailed from time to time in VICI’s filings with the Securities and Exchange Commission. VICI does not undertake any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, except as may be required by applicable law.
